SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement ACN Newswire

SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).During the year, loss for the year was approximately RMB105.0 million, decreased by RMB80.1 million from RMB185.1 million for the year ended 31 December 2024. The Company focused on SM17 Phase 1b clinical, transformation bridging study and preparation of Phase 2 clinical trial in 2025, of which the cost was less than large scale clinical studies in 2024. As at 31 December 2025, total funding available to use was approximately RMB351.5 million, representing a significant increase compared to RMB141.4 million as at 31 December 2024. During the year, the Group gained support from well-known institutional investors including Foresight, Fullgoal, and E Fund, completed two rounds of new share subscriptions under general mandate and successfully raised an aggregate amount of approximately HK$493.7 million in net proceeds. This drove net cash flows from financing activities for the Reporting Period to approximately RMB329.4 million, providing sufficient funding to support subsequent R&D and clinical advancement.SM17 Achieves Multiple BreakthroughsSM17 is a global first-in-class humanised monoclonal antibody (mAb) targeting the receptor for IL-25, which is capable of modulating Type II allergic reaction by targeting the receptor of a critical “alarmin” molecule interleukin-25 (IL-25). The compound has the potential for treating atopic dermatitis (AD), Inflammatory Bowel Disease (IBD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF).In the field of atopic dermatitis (AD), SM17 precisely targets upstream drivers of Type 2 immune responses by blocking IL-25, a key “alarmin” cytokine, thereby suppressing the inflammatory cascade at its source. While currently approved AD therapies, including biologics, can significantly improve Eczema Area and Severity Index (EASI) scores and patients’ quality of life, current drugs under development or on the market cannot simultaneously meet the clinical needs for rapid itch relief, skin lesion recovery, and good safety profiles, indicating substantial unmet market demand. SM17’s key innovation lies in its upstream modulation of the Th2 inflammatory cytokine pathway via IL-25 receptor inhibition, thereby suppressing multiple downstream pathogenic signaling pathways. Preclinical studies have demonstrated its potential for rapid itch relief, significant skin lesion recovery, and a favorable safety profile, directly addressing the key limitations of current therapies.In April 2025, SM17 achieved encouraging positive results in a Phase 1b study in China for the treatment of moderate to severe atopic dermatitis (AD): 12-week topline data after unblinding showed that in the high dose group, 91.7% of patients achieved pruritus relief (NRS-4), 75% achieved skin healing (EASI 75), and 41.7% achieved clear or almost clear signs of AD (IGA0/1). These results significantly outperform IL-4/IL-13 monoclonal antibodies and demonstrate a significantly better safety and tolerability profile than Janus Kinase inhibitors (JAK inhibitors), making SM17 potentially the first-in-class and best-in-class therapeutics which can simultaneously achieve rapid onset of action on pruritic relief, skin healing with a good safety profile. Study results of SM17 were published in various leading international journals. Phase 2 clinical trial for AD is expected to be entered into as early as mid-2026.On 11 December 2025, an Investigational New Drug application (“IND”) for SM17 in the indication of IBD was filed with and accepted by the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration of China (“NMPA”), and the IND was subsequently approved in February 2026. This IND submission represents an important step toward expanding SM17’s therapeutic scope beyond AD to IBD, including Crohn’s disease (“CD”) and ulcerative colitis (“UC”), which are chronic, debilitating conditions with significant unmet medical needs. In October 2025, the first cohort of healthy subjects was dosed in a Phase 1 bridging clinical trial for the route of administration conversion in China. As of 31 December 2025, a total of 30 healthy subjects had been enrolled and our follow-up visits for all healthy subjects were completed in February 2026. This bridging study is expected to be completed by the second quarter of 2026. Data from this study will be leveraged to support the progression of the IBD indication directly to Phase 2 clinical development.Early-Stage Pipelines Drive Continuous Innovation GrowthIn terms of early-stage pipeline development, the Company continues to make steady progress. In June 2025, Its partner, Everest Medicines, has announced positive results from the Phase Ib/IIa clinical trial of EVER001 (SinoMab’s SN1011) for the treatment of primary membranous nephropathy (PMN), further enhancing the commercial value of the pipeline.At the same time, multiple early-stage R&D programs are progressing steadily. Anti-CGC antibody is an in-house developed, first-in-class humanised anti-γc antibody. Our in vitro assays suggested that our antibody could suppress inflammation and autoimmunity driven B, T and NK cell activation. Animal studies demonstrated that our antibody could be a potential therapeutic agent for the treatment of vitiligo, alopecia areata and possibly other autoimmune diseases through the modulation of immune cell expansion, autoreactivity and tissue infiltration. We are currently in the process of CMC optimisation and toxicology studies for our antibody and plan to submit our IND application for the treatment of alopecia areata by the fourth quarter of 2026 at the earliest.Bispecific antibody candidate is a novel, bispecific antibody targeting Receptor activator of the nuclear factor kappa-B ligand (RANKL) and sclerostin for bone-related indications. bsAb processes differential mechanisms of action tailored for the treatment of osteoporosis. Our in-house in vitro and in vivo studies demonstrated our candidate to have enhanced efficacy over market-approved antibodies such as Denosumab and Romosozumab. We are currently in the process of optimising CMC and testing toxicity in non-human primates and plan to submit our IND application by the first half of 2027 at the earliest.Expanding Strategic Partnerships and Gaining Strong Industry RecognitionsIn August 2025, the Company entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Institute of Advanced Studies Hong Kong Limited (“SYSU-IAS”). Under the cooperation agreement, the Company enjoys direct access to SYSU-IAS’s comprehensive laboratory facilities and valuable data resources, as well as access to primate and non-primate animal studies supply resources, to accelerate the development of innovative drugs and promote the translation of scientific research into clinical applications worldwide. Furthermore, the Company is actively exploring the feasibility of using artificial intelligence (AI) technology for new target identification.In January 2026, the Company was invited to participate in the J.P. Morgan Healthcare Conference, where it shared its progress in the autoimmune field with multiple multinational pharmaceutical companies (MNCs) and investors.With the support of our strong R&D capabilities, extensive pipeline assets and refined operational management, we are thrilled to obtain renowned awards during the year, including the 2nd “New Quality Productive Forces Enterprise Award” jointly presented by the Greater Bay Area Family Office Association and the Hong Kong International Family Office Association, as well as the “Most Valuable Pharmaceutical Company Award” presented by Zhitong Finance.Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, comments: "In 2025, we demonstrated the global competitiveness of our innovative pipeline with solid clinical data. The outstanding performance of SM17 in AD and its indication expansion to IBD signify our continuous transition from single-product R&D to the realisation of platform value. Looking ahead to 2026, the biopharmaceutical industry has been accelerating into the “Biotech 3.0 Era”, which is characterised by innovation-driven development, multidisciplinary integration, and intelligent processes across the entire supply chain. We are well-positioned to capture the historic opportunity of the rapid growth of out-licensing deals in China’s biopharmaceutical industry, continue to advance the clinical development of our core pipelines, and deepen our international partnership footprint. Relying on our solid cash reserves, full-spectrum capabilities across the industry chain and the principle of differentiated innovation, we strive to maximize the returns of shareholders in the long run and provide life-changing breakthrough therapies for patients.”About SinoMab BioScience LimitedSinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies. This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.Investor and Media InquiriesContact Person: Bunny LeeCitrus JiangWendy HuangPhone: (852) 5316 9995Email: ir_sinomab@zhenzhuoglobal.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
同仁堂醫養(02667.HK)基石鎖定逾46% “百年中醫第一股”認購進入最後倒計時 ACN Newswire

同仁堂醫養(02667.HK)基石鎖定逾46% “百年中醫第一股”認購進入最後倒計時

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 這家承載356年品牌傳承的中醫醫療服務龍頭近日正在港股招股,背靠"老字號",補齊了同仁堂集團"制藥-零售-醫養"大健康生態圈的最後一塊拼圖 。本次全球發售1.08億股,其中香港公開發售約10%,國際發售約90%。基石投資者已鎖定占發行規模逾46%,基石占比接近最高限額。機構真金白銀入場:基石比例高,機構參與熱度足數據是最誠實的信號。據招股書披露,基石投資者航空港科技資本(香港)及Aurora SF將按發售價認購總金額約3.89億港元的股份,占全球發售規模逾46%,這一比例在近期港股IPO中處於較高水平。基石鎖定比例高意味著上市後可流通籌碼有限,對二級市場價格支撐更強。此外,基石鎖定期超過傳統規定的6個月,進一步增強了市場的預期。獲客成本極低:僅為同行業的六十分之一在醫療服務行業,獲客成本是決定盈利天花板的關鍵變量。同仁堂醫養背靠始創於1669年的"同仁堂"金字招牌,品牌壁壘的經濟價值可以用一個數字概括:2024年推廣費占收入比例僅約0.2%。然而就診人次卻從2022年的132.1萬飆升至2024年的297.7萬,CAGR高達50.1%。2025年前9月達253.6萬,同比再增21.5%。會員從43.6萬增至76.7萬(2025年9月),複購粘性強勁。隨著收入規模擴大,同行需要花在營銷上的每一分錢,對同仁堂醫養而言幾乎都可以直接轉化為利潤。這是任何競爭對手都無法在短期內複制的護城河。盈利拐點已確立:經調整淨利潤增長29%對於處於上市窗口的成長型企業,投資者最關心的是:盈利趨勢是向上還是向下?答案很明確——向上,且加速。財務數據顯示,公司已展現出穩健的盈利能力。2022年至2024年,公司已由虧損923萬元轉為盈利4620萬元,經調整淨利潤達6173萬元,增長達到29%;毛利同期從1.43億元增至2.22億元,年複合增長率為 24.8%;2024年現金轉化率87.2%,有息債務占比僅11.56%,持有現金2.25億元,盈利質量顯著提升 。同仁堂醫養當前的發展階段與固生堂上市時高度相似,盈利能力剛進入釋放通道,增長最快的階段可能尚未到來。複制增長階段:計劃新增20家醫療機構中醫醫療服務是業績基本盤,公司已構建包含25家醫療機構的分級診療網絡,其中自有醫療機構12家,管理醫療機構12家,此外還有1家互聯網醫院提供線上診療服務。截至2024年就診人數約300萬人,CAGR高達50.12%;2025年前9月約253.6萬,同比再增21.5%;會員數量約74萬人,合作藥店約500餘家。作為同仁堂集團打開增長空間的核心業務,醫療服務板塊規模還需要更強力的支持與擴張。根據其募集資金使用披露,該公司計劃新收購5家醫療機構、以輕資產的方式新建5家醫療機構,並額外向5-10家醫療機構提供管理服務。可見,其未來快速擴張的戰略清晰,"收購+輕資產新建+管理輸出"三路徑協同。非"名醫驅動":依靠標准化"體系驅動"對中醫醫療服務企業而言,最大的成長瓶頸在於"名醫能否複制"。同仁堂醫養正在用一套體系化的方法論回答這個問題。公司向上遊延伸,自建了供應鏈體系,完成了端到端的產業鏈閉環。除藥品外,健康產品銷售也實現了品牌價值的商業化變現。公司已獲授權在浙江省獨家銷售同仁堂爆款安宮牛黃丸系列產品,截至最後實際可行日期,公司已向超過4000家機構客戶銷售健康產品及其他產品。此外,公司將雲數字化系統紮根進網絡內每一家醫療機構,通過實時數據分析及管理,用智能系統代替"院長",正在向"人機協作式"新型連鎖醫療管理方式過渡。讓增長不再完全依賴於個別名醫的"人治",而是依托可複制的運營體系、數字化中臺和人才培養機制,實現規模化、標准化擴張。AI+中醫:醫藥數據壁壘深厚作為同仁堂集團在中醫服務領域唯一戰略性布局的載體,同仁堂醫養正站在傳統中醫與人工智能交匯的曆史拐點上 。同仁堂集團近期積極推動AI技術在中醫藥領域的落地應用,已與小米聯合打造"AI智能中醫藥健康服務智能體",將傳統中醫智慧與現代AI技術深度融合,形成"咨詢—建議—服務—購藥"的服務閉環 。展望未來,萬億規模的中醫醫療服務市場正迎來龍頭整合的黃金窗口期。同仁堂醫養以多輪驅動的發展模式、穩健的財務基礎及AI技術的前瞻布局,不僅完成了老字號資本版圖的最後一塊"拼圖",更開啟了中醫服務與前沿科技深度融合的新紀元。隨著上市募集資金的到位,相信同仁堂醫養有望加速推進核心業務的全面AI轉型,在萬億級中醫醫療服務市場中持續鞏固龍頭地位,引領行業邁向智能化新時代。轉載自格隆匯 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
嘀嗒出行(02559.HK)公佈2025年全年業績 經調整淨利潤達1.38億元人民幣 ACN Newswire

嘀嗒出行(02559.HK)公佈2025年全年業績 經調整淨利潤達1.38億元人民幣

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 中國領先的技術驅動移動出行平台嘀嗒出行(「嘀嗒」或「公司」,股票代碼:02559.HK)公佈了截至2025年12月31日止年度的經審計綜合年度業績。財務亮點:-截至2025年12月31日止年度,收入為人民幣5.02億元,2024年同期為7.87億元。-截至2025年12月31日止年度,毛利為人民幣3.33億元,2024年同期為5.67億元。-截至2025年12月31日止年度,淨利潤為人民幣1.30億元,2024年同期為10.04億元。-截至2025年12月31日止年度,經調整淨利潤(非國際財務報告準則計量)為人民幣1.38億元,而2024年同期為2.21億元。運營亮點:-截至2025年12月31日止年度,交易總額達人民幣47億元,訂單總數達到8090萬。-截至2025年12月31日,註冊用戶數超過4.15億。-截至2025年12月31日,認證私家車主數量達到約2100萬。業務展望:出行相關業務2025年是嘀嗒出行從專注于順風車的平台,向更為綜合的出行及車輛服務平台轉型的關鍵之年。2025年,嘀嗒出行推出了聚合打車業務,來進一步豐富平台的出行場景,使「中短途+立即出發」的即時出行需求與順風車「中長途+預約出行」的場景形成有效互補,增強用戶在不同出行決策場景下的選擇彈性。嘀嗒出行還開啟了二手車交易線索業務,拓展車輛全生命週期的業務範圍,並提升車主生態的用戶參與度。嘀嗒出行認為,順風車在中國仍處於早期發展階段,有潛在的巨大市場需求還未被充分釋放,而順風車的益處還未被完全認知。嘀嗒出行將持續致力於創新,圍繞平台的出行場景,繼續發展平台獨特的競爭優勢和價值,以更好地服務用戶群體。未來,嘀嗒出行計劃進一步發展聚合打車業務及其他出行相關服務,並持續擴展服務品類。有關嘀嗒出行截至2025年12月31日止年度全年業績公告的完整內容,請訪問:https://manager.wisdomir.com/files/594/2026/0320/20260320220001_60101381_en.pdf關於嘀嗒出行嘀嗒出行(「嘀嗒」或「公司」,股票代碼:02559.HK)是中國領先的技術驅動型出行平台。公司通過提供順風車平台服務,為乘客和出行路線及時間相近的私家車主進行匹配,從而在不增加環境負擔的前提下創造了更多運力。公司還提供聚合打車服務,以滿足更多元的出行場景需求。嘀嗒出行致力於讓出行生態更綠色、更高效,讓每一次出行體驗溫暖而愉悅。前瞻性聲明本新聞稿包含有關公司業務前景、預測業務計劃和增長戰略的前瞻性陳述。這些前瞻性陳述基於公司目前信息,並基於本新聞稿發佈時的前景進行陳述。它們基於某些期望、假設和前提,其中一些是主觀的或不可控的,可能被證明是不正確的,未來可能無法實現。前瞻性陳述背後存在大量風險和不確定性。有關這些風險和不確定性的更多信息,請參閱公司網站上的其他公開披露文件。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Dida Inc. (02559.HK) Announced 2025 Annual Results, RMB 138 Million Adjusted Net Profit ACN Newswire

Dida Inc. (02559.HK) Announced 2025 Annual Results, RMB 138 Million Adjusted Net Profit

HONG KONG, March 24, 2026 - (ACN Newswire via SeaPRwire.com) – Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK), a leading technology-driven mobility platform, announced the audited consolidated annual results for the year ended December 31, 2025.Financial Highlights:- Revenue was RMB502.4 million for the year ended December 31, 2025, compared to RMB787.2 million for the year ended December 31, 2024.- Gross profit was RMB332.9 million for the year ended December 31, 2025, compared to RMB567.0 million for year ended December 31, 2024.- Net profit was RMB129.8 million for the year ended December 31, 2025, compared to RMB1,004.3 million for the year ended December 31, 2024.- Adjusted net profit (non-IFRS measure) was RMB137.9 million for the year ended December 31, 2025, compared to RMB221.4 million for the year ended December 31, 2025.Operation Highlights:- Gross transaction value amounted to RMB4.7 billion and the total number of orders reached 80.9 million for the year ended December 31, 2025.- Registered users reached over 415 million as of December 31, 2025.- The number of certified private car owners reached approximately 21 million as of December 31, 2025.Business OutlookMobility-related business 2025 marked a pivotal year as the Company transitioned from a single-focus carpooling platform toward a more integrated mobility and vehicle services platform. In 2025, the Company launched ride-hailing aggregation platform services to diversify service offerings. Such services are intended to complement the carpooling business by addressing additional mobility scenarios, including short-to-medium distance and immediate travel needs, in addition to the medium-to-long distance and pre-arranged travel scenarios typically served by carpooling. The Company also commenced used car trading referral services to expand business scope along the vehicle ownership lifecycle and enhance engagement within the Company’s car owner ecosystem. The Company believes carpooling in China is still at its early stage of development, with significant market demand yet to be fully released and the benefits of carpooling not fully recognized by the public. The Company will remain committed to innovation as the Company continues to develop unique competitive strengths and value around mobility scenarios to better serve the user base. In the future, the Company plans to further develop ride-hailing aggregation platform services and other mobility-related services and to continue to expand service offerings.For the full announcement of Dida for the annual results ended December 31, 2025, please visit:https://manager.wisdomir.com/files/594/2026/0320/20260320220001_60101381_en.pdf About Dida Inc.Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK) is a leading technology-driven mobility platform in China. The Company creates more transit capacity with less environmental impact by providing carpooling marketplace services to pair up riders with private car owners if they are heading in similar directions at compatible times. It also provides ride-hailing aggregation platform services to address additional mobility scenarios. Dida makes the mobility ecosystem greener and more efficient, and each trip experience warm and enjoyable.Forward-Looking StatementsThis press release contains forward-looking statements relating to the business outlook, forecast business plans and growth strategies of the Company. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond the control. These forward-looking statements may prove to be incorrect and may not be realized in future. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding these risks and uncertainties is included in the other public disclosure documents on the corporate website. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
百年民族品牌拔頭籌 同仁堂醫養領航中醫發展 ACN Newswire

百年民族品牌拔頭籌 同仁堂醫養領航中醫發展

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 3月20日,"同仁堂"旗下核心醫療平臺--北京同仁堂醫養投資股份有限公司,(簡稱"同仁堂醫養")正式啟動香港公開發售,邁出登陸香港聯交所主板的關鍵一步。作為同仁堂集團唯一戰略聚焦於中醫服務的核心板塊,同仁堂醫養的此番亮相,不僅是一家企業的資本化進程,更標志著中國最具代表性的百年中醫品牌,正式將標准化"中醫診療"推向國際資本市場。根據招股文件,同仁堂醫養(股份代號:02667.HK)此次全球發售108,153,500股H股,其中香港公開發售占10,815,500股(可予重新分配),國際發售占97,338,000股。每手500股,入場費約為4,191.85港元,發售價範圍定於每股7.30港元至8.30港元,以發售價中位數7.80港元計算,經扣除相關費用後,集資淨額預計約為7.71億港元。中金公司擔任其獨家保薦人及獨家整體協調人,設置綠鞋。航空港科技資本、Aurora SF兩大基石投資者已提前鎖定46%份額,彰顯對公司長期價值的信心。百年品牌鑄就競爭壁壘,分級網絡構建服務版圖在中國醫療健康行業的眾多參與者中,同仁堂醫養擁有一項難以複制的核心資產--357年同仁堂品牌背書。招股書顯示,同仁堂醫養定位於同仁堂集團旗下專注於中醫醫療服務的戰略子公司,聚焦中醫醫療服務核心賽道,構建"醫養結合、線上線下一體化"的特色服務體系,業務涵蓋中醫醫療服務、機構管理服務、健康產品銷售三大核心板塊,形成多層次、全周期的健康服務供給。品牌壁壘的量化體現尤為突出。數據顯示,公司推廣費用率僅為0.2%,遠低於行業平均水平。與行業平均銷售費用率約為12%-13%相比,同仁堂醫養低於其約60倍。這一數據意味著,當同業仍在大規模投入營銷獲客時,同仁堂醫養的患者已憑品牌認知主動就診--這是百年老字號鑄就的天然流量入口,也是競爭對手無法在短期內複制的結構性優勢。中醫分級網絡仍為行業先鋒。在業務布局方面,同仁堂醫養已建成分級中醫醫療服務網絡,擁有12家自有線下醫療機構以及1 家互聯網醫院,同時向12 家公立線下醫療機構提供管理服務,覆蓋北京、浙江、上海、山西、貴州、遼寧、陝西等核心區域,形成"連鎖醫院-基層醫療機構-互聯網醫院"的三級架構,實現了全國服務網絡的高效協同。其中,連鎖醫院承擔疑難重症的多學科診療職能,基層醫療機構(門診部、診所、社區醫院)負責常見病、慢病管理和日常健康維護,互聯網醫院則打破時空限制,將服務半徑延伸至全國。三級架構分層協同、高效配置醫療資源,為後續全國化擴張奠定了可複制的基礎模型。品牌及網絡效能持續高速釋放。數據顯示,2024年其網絡內總就診人次達297.7萬,2022年至2024年的複合年增長率高達51.9%。會員數量從43.6萬人增至76.7萬人,客戶黏性與複購率穩步提升。旗下醫療機構實現醫保定點全覆蓋,患者就醫便利性與支付可及性得到有力保障。多輪驅動式外延擴張,整合賦能標准化連鎖本次 IPO 核心看點,在於同仁堂醫養以"戰略性並購、輕資產新建及管理服務輸出"三種方式實現規模與質量雙躍升。公司立足百年品牌勢能,采取"網絡整合+標杆管理+全國複制"的擴張路徑,精准卡位區域優質中醫機構,快速補齊網絡、專科、客流與供應鏈全鏈路。2022年公司完成對浙江三溪堂保健院、三溪堂國藥館的控股收購,一舉拿下浙江區域安宮牛黃丸系列獨家經銷權,打通醫療服務與健康產品協同變現通道;2024年相繼收購上海承志堂等醫療機構控股權,強勢切入長三角核心市場,實現京滬浙多點聯動。衡量一家連鎖醫療企業並購戰略成敗的關鍵,不在於"買了多少",而在於"整合得多好"。同仁堂醫養依托采購協同平臺、雲HIS與BIS數字化系統,對收購機構實施醫療質量、運營效率、成本管控一體化管理,推動被投機構快速融入同仁堂體系、釋放盈利潛力。與此同時,公司的管理服務毛利率超70%,與高毛利健康產品、穩定醫療服務業務形成互補,構建韌性極強的盈利結構。同仁堂醫養並非傳統的重資產醫院集團,而是走出一條"輕資產管理式"醫療集團路徑,為未來規模化擴張提供了更具彈性的增長空間。基本面穩定有韌性,行業打開增長空間財務表現也印證同仁堂醫養的發展模式。2022-2024年,公司營收從9.11億元增至11.75億元,收入CAGR達13.6%,毛利潤CAGR更高達24.8%;2024年淨利潤4620萬元、經調整淨利潤6173萬元,同比增長29.0%,呈現"增收更增利"的高質量增長特征。期間費用率從2022年的17.1%下降至2025年前三季度的13.6%,下降3.5個百分點,標准化運營和數智化轉型的效率紅利持續釋放。經營性現金流轉化率達87.2%,賬面現金2.25億元,利息覆蓋充裕,財務安全邊際充足。企業正在從"規模擴張期"平穩過渡至"利潤釋放期"--這正是連鎖醫療企業盈利質量躍升的關鍵階段。從行業趨勢來看,中醫醫療服務正處於政策驅動與需求擴容的雙重紅利期。據弗若斯特沙利文數據,中國中醫醫療服務市場規模預計2029年將達1.62萬億元,2024年至2029年CAGR為9.9%。在人口老齡化持續深化和"全民養生"消費趨勢下,中醫醫養賽道的確定性增長邏輯清晰。此外,在中醫藥振興政策與人口老齡化需求雙重驅動下,中醫醫療服務行業進入整合提速期。同仁堂醫養憑借品牌壁壘、並購整合能力、標准化複制體系三大核心優勢,在行業集中度提升過程中占據主動。本次IPO募集資金將重點投向醫療網絡擴張、服務能力升級等。同仁堂醫養以資本為翼,以醫養為本,將百年民族品牌底蘊轉化為現代醫療服務競爭力。此次港股上市,不僅打開全國化擴張空間,更為投資者分享中醫醫養黃金賽道紅利,領航中醫藥醫療服務行業高質量發展新征程。轉載自中國證券報 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
TINGYI (CAYMAN ISLANDS) HOLDING CORP. Business Momentum Sustained in 2025, United for a New Journey, with GPM Rising to 34.8%, Profit Attributable to Shareholders Up 20.5% YoY ACN Newswire

TINGYI (CAYMAN ISLANDS) HOLDING CORP. Business Momentum Sustained in 2025, United for a New Journey, with GPM Rising to 34.8%, Profit Attributable to Shareholders Up 20.5% YoY

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - On March 23, 2026, Tingyi (Cayman Islands) Holding Corp. (0322.HK, the “Company”, together with its subsidiaries, the “Group”) is pleased to announce its 2025 annual results. In 2025, amid drastic changes in consumer behaviours and a complex market environment, the Group remained firmly committed to the consumer-centric approach, advanced the high-quality development in a coordinated manner, promoted product innovation and upgrades to precisely meet the demands of diverse scenario-based needs, while accelerating the expansion into high-growth channels. It comprehensively improved overall operational efficiency and drove steady growth of all key financial indicators. For the twelve months ended on December 31, the Group’s revenue decreased by 2.0% year-on-year to RMB 79.068 billion. Among which, the revenue from the Instant Noodles Business was RMB28.421 billion, while the revenue from the Beverages Business was RMB50.123 billion. The gross profit margin grew 1.7 percentage points to 34.8% year-on-year, EBITDA increased by 10.2% year-on-year to RMB 10.607 billion. The profit attributable to shareholders of the Company increased significantly by 20.5% year-on-year to RMB4.501 billion. The directors recommended the payment of a final dividend and a special final dividend of RMB39.92 cents and RMB39.92 cents per ordinary share respectively. Dividend payout ratio for the year remained at 100%.Financial Summary For the twelve months ended 31 December RMB’00020252024ChangeRevenue79,068,02280,650,914↓ 2.0%Gross margin34.8%33.1%↑ 1.7ppt.Gross profit of the Group27,531,70426,695,643↑ 3.1%EBITDA10,606,5229,627,802↑ 10.2%Profit for the period5,175,8524,322,135↑ 19.8%Profit attributable to owners of the Company4,500,6983,734,429↑ 20.5%Earnings per share (RMB cents) Basic79.8666.28↑ 13.58 centsDiluted79.8466.28↑ 13.56 centsAs at 31 December 2025, cash at bank and on hand (including long-term time deposits) was RMB19,486.056 million, representing an increase of RMB3,483.388 million when compared to 31 December 2024. Gearing ratio was -29.8%.In 2025, China's economy demonstrated resilience with a 5% year-on-year GDP growth. However, the food and beverage market entered into the stage of stock competition and demand upgrading for functional and emotional values. Brand, quality, and flavors remained key drivers of purchasing decisions. Additionally, emerging formats such as instant retail, snack discount stores, and membership stores had brought about drastic changes in channels and consumer behaviors. Against the backdrop of intensifying market competition and evolving consumption patterns, a company's core competitiveness increasingly lies in building a strong moat for their core brands. Those that continuously drive product innovation and channel optimization around consumer needs will be more agile in capturing market opportunities, strengthening consumer trust, and ultimately achieving high-quality and sustainable long-term development.In 2025, the gross profit of the Instant Noodles business improved steadily. The Group’s revenue from the Instant Noodles Business was RMB28.421 billion, which grew slightly year-on-year, accounting for 35.9% of the Group’s total revenue. During the year, due to favorable raw material prices and selling prices, the gross profit margin of instant noodles expanded by 1.1 percentage points year-on-year to 29.7%, and the profit attributable to shareholders of the Company for the year of 2025 in the Instant Noodles Business increased significantly by 10.1% year-on-year to RMB 2.252 billion, driven by the year-on-year increase in gross profit margin. During the year, in the face of intensifying industry competition, the Instant Noodles Business steadily advanced its core strategy of “consolidating blockbuster products, seizing the popular flavors track, and cultivating innovative products.” By continuously improving the product portfolio and forging deep collaborations with popular IPs, it effectively amplified brand presence and steadily optimized gross margin structure. On the product front, the business relied on deep cultivation of core blockbuster products and iterative flavor upgrades, while closely aligning with evolving consumer trends to precisely target the health-focused and premium market segments, tapping into new growth opportunities. On the marketing front, it leveraged mainstream social platforms such as Bilibili and Xiaohongshu to conduct omnichannel communication, combined with cross-industry collaborations with well-known IPs to reinforce the brand perception of high-end and convenient consumption. As a result, brand influence and market recognition improved significantly. Meanwhile, guided by aerospace-grade quality standards, the business promoted the full application of aerospace patented temperature control technology in the production line, fully demonstrating the brand’s differentiated advantages in product quality and technological innovation.The Beverages Business firmly executed the strategy of “consolidating core products and developing innovative products”, the revenue from the Beverages Business was RMB50.123 billion, accounting for 63.4% of the Group’s total revenue. During the year, due to favorable raw material prices and optimized product mix, the gross profit margin of Beverages expanded by 2.2 percentage points year on-year to 37.5%. Driven by a year-on-year expansion of gross profit margin, the profit attributable to shareholders of the Company in the Beverages Business for the year of 2025 increased significantly by 18.5% year-on-year to RMB 2.274 billion. During the year, the Beverages Business strengthened its core category advantages and proactively positioned itself in emerging tracks, establishing a collaborative growth model across the full product portfolio. On the product front, while consolidating core products, it continuously expanded into incremental growth segments by launching high-quality sugar-free offerings and aligning with the wellness consumption trend to create herbal wellness scenarios, successfully opening up new growth spaces such as products made from homologous medicinal and food materials. On the marketing front, the Company deepened IP collaborations to broaden audience reach, enhanced its presence in cultural tourism channels and high-end hotel partnerships, and targeted premium consumption scenarios. These efforts consistently elevated brand value, providing strong support for the business to achieve steady operations and sustainable growth.Mr. Wei Hong-Chen, Chief Executive Officer, commented, “As the first year of the 15th Five-Year Plan period, 2026 is expected to see expanding domestic demand become a key driver of economic growth under a more proactive and effective macroeconomic policy, while the consumer market will also usher in a critical window of profound transformation. The food and beverage industry will closely follow the theme of high-quality development, and consumption stratification will become more refined. Functional attributes, emotional resonance, and green concepts are shifting from trends to mainstream factors, becoming core elements driving brand growth. In the face of opportunities and challenges in the new cycle, the Group will be guided by the spirit of “Back to Day 1” as its strategic direction, embracing the efficiency, agility and entrepreneurial drive of our founding days, and building a platform that encourages honesty, bold experimentation and mutual growth, thus fully unleashing the vitality of all employees. While unleashing organizational vitality, we will continue to strengthen our foundational R&D capabilities and digital operation systems. Rooted in the health needs of the nation, we will drive product iteration and upgrades through technological innovation, continuously elevate product value, and align high-quality supply with the evolving consumption landscape. Adhering to the “economic-ESG” sustainable development philosophy, we will internalize social responsibility as the foundation of our development, solidify user trust through quality products, build a brand moat with long-term value, and create a sustainable and stable return system for shareholders, propelling the Group toward steady and sustained progress in the new stage of high-quality development.”About Tingyi (Cayman Islands) Holding Corp. (0322.HK)Tingyi (Cayman Islands) Holding Corp. (the “Company”), and its subsidiaries (the “Group”) specialise in the production and distribution of instant noodles and beverages in the People’s Republic of China (the “PRC”). The Group started its instant noodle business in 1992, and expanded into instant food business and beverage business in 1996. In March 2012, the Group further expanded its beverage business by forming a strategic alliance with PepsiCo for the beverage business in the PRC. The Company exclusively manufactures, bottles, packages, distributes and sells PepsiCo soft drinks in the PRC. After years of hard work and accumulation, “Master Kong” has become one of the best-known brands among consumers in the PRC.For enquiries, please contact:Investor EnquiriesInvestor Relations Team, Tingyi (Cayman Islands) Holding Corp.E-mail: ir@tingyi.comChristensen China LimitedStephanie ChenE-mail: stephanie.chen@christensencomms.comTel: +852 2117 0861 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
康師傅控股有限公司2025年業務持續向好 凝心聚力再啟新程 ACN Newswire

康師傅控股有限公司2025年業務持續向好 凝心聚力再啟新程

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 2026年3月23日,康師傅控股有限公司(0322.HK,以下簡稱「公司」,連同其附屬公司「集團」)發佈2025年年度業績公告。2025年,在消費行為劇烈變革與市場環境複雜多變的背景下,本集團始終堅持以消費者為中心,統籌推進高質量發展,推動產品創新升級,精准滿足多元場景需求,同時加速開拓高增長渠道,全面提升整體運營效能,推動各項財務指標穩健發展。截至2025年12月31日止十二個月,集團收益同比衰退2.0%至790.68億人民幣。其中,方便面事業收益284.21億人民幣,飲品事業收益為501.23億人民幣。毛利率同比提高1.7個百分點至34.8%,EBITDA同比增長10.2%至106.07億人民幣,本公司股東應佔溢利同比成長20.5%至45.01億人民幣。董事會建議派發末期股息每股普通股人民幣39.92分及特別末期股息每股普通股人民幣39.92分,全年派息率達100%。財務摘要 截至12月31日止12個月 人民幣千元2025年2024年變動收益79,068,02280,650,914↓ 2.0%毛利率(%)34.8%33.1%↑ 1.7個百分點集團毛利27,531,70426,695,643↑ 3.1%扣除利息、稅項、折舊及攤銷前盈利(EBITDA)10,606,5229,627,802↑ 10.2%本期溢利5,175,8524,322,135↑ 19.8%本公司股東應占溢利4,500,6983,734,429↑ 20.5%每股溢利(人民幣分) 基本79.8666.28↑ 13.58分攤薄79.8466.28↑ 13.56分於2025年12月31日之銀行存款及現金(含長期定期存款)為人民幣19,486,056千元,相較2024年12月31日增加人民幣3,483,388千元,淨負債與資本比率為-29.8%。2025年,中國經濟在GDP同比5%的增長中展現韌性。但食品飲料市場進入存量博弈,以及對功能價值與情緒價值需求升級階段。品牌、品質與風味仍是購買決策的重要驅動因素。此外,即時零售、零食折扣店、會員店等新興業態帶來渠道與消費行為劇烈變革。在市場競爭日趨激烈、消費行為持續演變的背景下,企業的核心競爭力愈發體現在核心品牌的護城河建設。能夠圍繞消費者需求,持續推動產品創新與渠道優化的企業,將更敏捷地捕捉市場機遇,鞏固消費者信任,進而實現高質量、可持續的長遠發展。2025年,方便面事業的毛利結構持續改善。方便面事業收益為284.21億人民幣,同比微幅增長,占集團總收益35.9%。年內,因原材料價格及售價有利,使方便面毛利率同比提高1.1個百分點至29.7%,由於毛利率同比提高帶動,令方便面事業2025年全年的本公司股東應占溢利同比大幅增長10.1%至22.52億人民幣。年內,面對日趨激烈的行業競爭,方便面業務扎實推進「鞏固大單品、佔領大口味賽道、培育創新產品」的核心戰略,通過持續完善產品矩陣,與熱門IP深度聯動,有效放大品牌聲量,穩步優化毛利結構。產品端,依託核心大單品深耕與口味迭代升級,同時緊密貼合消費趨勢變化,精准佈局健康化、高端化賽道,精准切入新增量市場。營銷端,依託B站、小紅書等主流社交平台開展全域傳播,疊加知名IP跨界合作,深化高端便捷的品牌認知,品牌影響力與市場認知度顯著提升。同時,以航天品質為引領,推動航天專利溫控技術在生產線全面落地應用,充分彰顯品牌在產品品質與科技含量的差異化優勢。飲品事業堅定實施「鞏固核心單品、發展創新產品」戰略。飲品事業整體收益為501.23億人民幣,占集團總收益63.4%。年內,因原材料價格有利及產品組合優化,使飲品毛利率同比提高2.2個百分點至37.5%。由於毛利率同比提高帶動,令飲品事業2025年全年本公司股東應占溢利同比大幅提高18.5%至22.74億人民幣。年內,飲品事業通過深化核心品類優勢與前瞻性佈局新興賽道,構建全品類協同增長格局。產品端,在穩固核心單品的基礎上,持續拓展增量賽道,推出高品質無糖產品,並緊扣養生消費趨勢,打造草本養生場景,成功開闢藥食同源等新增量空間。營銷端則持續強化IP深度合作拓寬受眾圈層,同時強化文旅渠道佈局及高端酒店合作,錨定高端消費場景,持續提升品牌價值,為業務實現穩健經營與可持續增長提供有力支撐。康師傅首席執行官魏宏丞先生表示:「2026年作為「十五五」開局之年,預計在更加積極有為的宏觀政策下,擴大內需將成為經濟增長的關鍵著力點,消費市場也將隨之迎來深度變革的關鍵窗口。食品飲料行業圍繞高質量發展主線持續演進,消費分層愈加精細,功能價值、情緒共鳴與綠色理念正從趨勢走向主流,成為驅動品牌增長的核心要素。面對新週期中的機遇與挑戰,集團將以「Back to Day 1」的精神為戰略引領,回歸創業初期的高效敏捷與狼性拼搏文化,打造敢講真話、勇於嘗試、共同成長的平台,充分激發全員活力。在釋放組織活力的同時,我們將持續夯實基礎研發能力與數字化運營體系,立足國民健康訴求,以科技創新驅動產品迭代升級,推動產品價值不斷躍遷,以高品質供給適配新消費結構。秉持「economic-ESG」可持續發展理念,我們將社會責任內化為發展底色,通過優質產品夯實用戶信賴,以長期價值構建品牌護城河,為股東打造可持續的穩健回報體系,推動集團在高質量發展新階段行穩致遠。」關於康師傅控股有限公司(0322.HK)康師傅控股有限公司(「本公司」)及其附屬公司(「本集團」)主要在中國從事生產和銷售方便面及飲品。本集團於1992年開始生產方便面,並自1996年起擴大事業至方便食品及飲品;2012年3月,本集團進一步拓展飲料事業範圍,完成與PepsiCo中國飲料事業之戰略聯盟,開始獨家負責制造、灌裝、包裝、銷售及分銷PepsiCo於中國的非酒精飲料。「康師傅」作為中國家喻戶曉的品牌,經過多年的耕耘與積累,深受中國消費者喜愛和支持。如有垂詢,請聯絡:投資者查詢康師傅控股有限公司投資者關係團隊電郵:ir@tingyi.com匯思訊中國有限公司陳敏芝電郵:stephanie.chen@christensencomms.com電話:+852 2117 0861 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
全景業務佈局+AI雙輪驅動 麥迪衛康業績扭虧為盈打開廣闊成長空間 ACN Newswire

全景業務佈局+AI雙輪驅動 麥迪衛康業績扭虧為盈打開廣闊成長空間

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 3月23日,麥迪衛康正式發佈2025年度業績公告。數據顯示,公司年內溢利約人民幣698萬元,盈利能力顯著修復,全年扭虧為盈,經營性現金流狀況持續好轉。業績改善主要得益于“AI+數字化”帶動核心主營業務持續穩健增長,疊加公司聚焦高毛利優質項目,有效帶動整體毛利水平顯著提升。此次公司財務表現展現出強勁的修復彈性,是公司發展歷程中的重要里程碑。一方面,標誌著公司聚焦主業、優化業務結構的戰略取得實質性成效,經營質量與盈利能力邁入全新階段,為後續穩健發展築牢財務根基;另一方面,充分印證公司核心業務具備強勁增長韌性與市場競爭力,高毛利項目佈局持續釋放效益,也為公司深化醫療健康服務佈局、拓展優質業務版圖注入更強信心,進一步鞏固行業競爭力與可持續發展能力。3C服務體系覆蓋全產業鏈 技術創新構築核心競爭力經營效率的跨越式進步,離不開公司清晰的業務佈局與精准的戰略定位。在業務佈局方面,麥迪衛康以創新數字醫療服務提供商為定位,打造獨具競爭力的「3C服務體系」,涵蓋專業醫學內容服務(Content)、高端學術會議服務(Conference)、企業市場推廣服務(Corporation)三大核心領域,形成了覆蓋醫療全產業鏈的服務閉環,為業務高質量發展筑牢根基。2025年,公司數字化醫學平台的運營步入高質量發展的新階段。該平台不僅實現了專業醫療群體的高密度覆蓋,更在海量的學術交流與衛教傳播中,構築起一套精準、專業且具備高度粘性的知識服務體系。這種深度的數字化轉型,不僅顯著提升了醫學內容的傳播效能與學術影響力,更在賦能醫生臨床決策、助力健康知識普及方面發揮了關鍵作用,轉化為推動行業進步的實質性力量,進一步鞏固了公司在數字醫療生態中的引領地位。持續的技術創新,是驅動麥迪衛康高質量增長的核心引擎。在技術研發領域,公司擁有多項軟件著作權與發明專利,自主研發的「長頸鹿」系列數智平台已吸引數十萬名醫生入駐,顯著提升醫療服務與運營管理效率。2024年,公司持續深化AIGC場景落地,創新推出「AI智能體+醫生眾創」模式,助力醫生回歸高價值診療與科研工作;同時依託區塊鏈技術成功獲得數據服務商資質,實現醫學內容確權與授權運營,為醫療數字化生態建設樹立行業標杆。2025年,公司深入推進AI智能體的研發與場景應用探索,致力於與醫療專業人士協同,打造「AI+人工」深度融合的醫學內容數據標註及版權內容生產體系,並與數字資產交易平台業務形成有機銜接。此外,依托专病管理AI智能体所取得的阶段性突破,公司正进一步将数智化能力向产业上下游延伸,前瞻性地探索智能专病机器人赛道;同时,通过对柏慧康生物的战略投资,公司正积极探索在多组学创新检测领域的落地应用并已取得阶段性进展,借此构建起立体化的医疗创新服务网络。全國服務網絡縱深覆蓋 打開長期價值成長空間依託成熟的業務體系與核心技術支撐,麥迪衛康已搭建起覆蓋全國的專業服務網絡。目前,公司在全國設立近10家經營機構,重點佈局北京、上海、南京等核心醫療樞紐城市,服務合作三級醫療機構超3000家,其中包括北京天壇醫院、阜外醫院等國內頂尖三甲醫院。同時,公司深度參與卒中中心、胸痛中心等重點專科建設,構建起縱向貫通、橫向協同的全域專科醫療服務體系,為業務高效落地與市場持續拓展提供了堅實保障。廣泛覆蓋的服務網絡與專業高效的服務能力,讓麥迪衛康積累起優質且多元的客戶群體,行業龍頭地位持續鞏固。在數字醫療領域,公司自有互聯網醫療平台已匯聚註冊醫生超5萬名、註冊患者近36萬人次,2025年線上諮詢量突破50萬次,同比增長超19%,實現優質醫療資源高效觸達,有效緩解醫療資源分配不均難題。從行業發展趨勢來看,在人口老齡化加劇、慢性病管理需求攀升、政策持續賦能及AI數字技術深度滲透等多重驅動下,中國數字醫療產業正迎來黃金髮展期,據中商產業研究院數據預測,2025年中國數字醫療市場規模預計達5800億元,2031年突破1.2萬億元,廣闊的市場增量為麥迪衛康這類具備核心技術壁壘與全鏈條佈局的領軍企業,提供了持續成長與價值釋放空間。麥迪衛康以「3C服務體系」為基座,以技術創新與服務升級為引擎,憑藉覆蓋全國的服務網絡、廣泛優質的客戶資源以及前瞻性的戰略佈局,在行業內構建了獨特的競爭優勢與地位。未來,隨著數字醫療產業的持續升溫與公司業務的不斷深化,公司將緊抓醫療智能化轉型的時代機遇,聚焦AI小模型賦能,全面拓展業務版圖,夯實「AI+區塊鏈」技術底座,探索搭建全流程智能閉環體系。同時以「醫學專業服務+數字化技術」雙輪驅動,持續拓寬業務邊界、優化內部運營效能,在數字醫療賽道上實現更高質量的發展,打開廣闊成長空間。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
International Career Institute Marks 20 Years with 100 Scholarships to Support Flexible Online Study ACN Newswire

International Career Institute Marks 20 Years with 100 Scholarships to Support Flexible Online Study

Sydney, Australia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - The International Career Institute (ICI) is marking its 20th anniversary with the launch of 100 scholarships, in a milestone initiative designed to widen access to flexible, career-focused online study. The scholarship announcement comes as more students look for practical ways to upskill, change careers or strengthen their professional credentials without putting work or family life on hold.New scholarships launched as International Career Institute celebrates two decades of career-focused educationTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10373/288837_60f2135b4402f876_001full.jpgOver the past two decades, the International Career Institute has built its reputation as an independent private provider of online education focused on practical, job-relevant learning. ICI offers 57 courses, has supported 58,453 students, and has learners in 191 countries, reflecting a substantial international footprint.The anniversary scholarship campaign is intended to do more than mark a birthday. It reflects a wider shift in the education market, where students are increasingly prioritising flexibility, affordability and direct career outcomes. ICI positions itself around exactly those needs: online delivery, self-paced study, personal tutor support, included course materials, flexible payment plans and career services aimed at helping graduates move into employment or advance in their chosen field.Applicants for the Leadership Scholarships are asked to demonstrate leadership potential or current leadership responsibilities and to complete an application process that outlines their background and motivation for study. Applicants facing financial disadvantage will be given priority. The scholarship forms part of a broader ICI scholarship offering and positions the initiative as a way to recognise leadership and help recipients take the next step in their development.For many adult learners, flexibility is not simply an added benefit; it is the condition that makes study possible. At the International Career Institute, students can study at their own pace, with no classes to attend and no additional textbooks or materials to purchase. Its online study model is structured around module-based written assessments rather than traditional exams, while students receive guidance and feedback from personal tutors throughout the course.Dr Michael Machica, Director of the International Career Institute, said the anniversary was both a celebration of the institution's history and a statement of intent for its future."Reaching 20 years is a proud milestone for the International Career Institute and a moment to reflect on how education has changed. From the beginning, our goal has been to make career-focused learning more flexible, more practical and more accessible for people whose lives do not fit the traditional study model. Over the next 20 years, we see ICI continuing to expand its reach, strengthen its industry relevance and help even more learners build meaningful careers through online education that works in the real world."That long-term focus on accessibility and employability remains central to the International Career Institute brand. Central to ICI's offering is tutor support, affordable pricing, interest-free payment plans, included materials and graduate career services. Those services include assistance with resumes, job searches, cover letters and interview preparation - features that help distinguish ICI in a competitive online learning market where students are increasingly outcome-focused.ICI's programmes are developed in consultation with industry experts and aligned with real-world job opportunities. That proposition - flexible study paired with career relevance - has become increasingly important as more learners seek education that fits around existing work, business, or family commitments while still contributing to employability and advancement.The release of 100 scholarships also gives the anniversary a broader public-interest dimension. In a cost-conscious environment, even motivated learners can hesitate when considering professional study. By offering scholarships focused on leadership and development, ICI is positioning its 20th anniversary not simply as a milestone but as an opportunity to invest in the next generation of professionals and career changers.Prospective students can explore scholarship eligibility, course options and the International Career Institute online study model through the institute's website, where they can also view course pages, student reviews and information about graduate support. For those considering a career change, promotion pathway or a more flexible way to formalise their skills, the anniversary scholarships create a timely reason to act.About International Career InstituteICI is an independent private provider of online education and training established in 2006. It offers career- and lifestyle-focused courses through a fully online, self-paced study model supported by personal tutors and graduate career services.Media ContactFor media enquiries, please contact:Email: info@ici.net.au Website: www.ici.net.auInternational Career InstituteTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10373/288837_60f2135b4402f876_002full.jpgTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/288837 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Doubleview Gold Clarifies Preliminary Economic Assessment Results for the Hat Project; Updated Scenario B NPV Increased to C$7.27 Billion ACN Newswire

Doubleview Gold Clarifies Preliminary Economic Assessment Results for the Hat Project; Updated Scenario B NPV Increased to C$7.27 Billion

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) ("Doubleview" or the "Company") provides clarification to its news release dated March 2, 2026, announcing the Preliminary Economic Assessment ("PEA") for the Company's 100% owned Hat Project in northwestern British Columbia.Following publication of the March 2, 2026 news release, Mineit Consulting Inc., the independent engineering firm responsible for the PEA, completed a further review of the application of certain processing cost assumptions relating to the scandium recovery circuit in Scenario B. As a result of this review, the after-tax NPV(5%) for Scenario B at consensus metal prices has been updated to C$7.27 billion from C$6.94 billion and IRR of 19%. The update also results in an increase in Scenario B after-tax NPV(5%) at spot metal prices to C$14.85 billion from C$14.52 billion and IRR of 32%.The updated Scenario B results further demonstrate the economic contribution of the scandium recovery circuit and increase the difference in after-tax NPV between the base case (Scenario A2) and Scenario B to C$547 million.The cobalt grade reported in Table 1 of the Company's March 2, 2026 news release was inadvertently shown as 0.78 g/t Co. The correct value is 78 g/t Co, consistent with Table 5 of the release. This discrepancy was limited to the summary table presentation and does not affect the PEA results or conclusions.These clarifications do not change the overall conclusions of the PEA and further highlight the strong economics of the Hat Project, including the potential value contribution from scandium recovery.Corrected highlights of the PEA reflecting the updated Scenario B economics are presented below.NPV:After-tax NPV(5%) of C$6.73 billion and IRR of 23% at Consensus Metal Prices After-tax NPV(5%) of C$13.53 billion and IRR of 39% at Spot Metal PricesNPV Including scandium and the associated processing circuit: After-tax NPV(5%) of C$7.27 billion and IRR of 19% at Consensus Metal PricesAfter-tax NPV(5%) of C$14.85 billion and IRR of 32% at Spot Metal PricesThree processing scenarios were evaluated-Scenario A1 (A1) a Cu-Au-Ag-Co flotation base case using current testwork recoveries1, Scenario A2 (A2), the same base case using expected recoveries1, and Scenario B (B), a Cu-Au-Ag-Co flowsheet with an added hydrometallurgical circuit and scandium recovery circuit, with results indicating the Project is financially attractive even without the scandium component.Highlights:Robust Project Economics: The PEA demonstrates a high-margin operation with an After-Tax NPV(5%) of C$4.96 billion (A1), C$6.73 billion (A2), or C$7.27 billion (B), and an IRR of 19% (A1), 23% (A2), or 19% (B) at analyst consensus metal prices2. Using a spot-price scenario3, the Project delivers a compelling after-tax NPV(5%) of C$11.05 billion (A1), 13.53 billion (A2), or C$14.85 billion (B) and an IRR of 34% (A1), 39% (A2), or 32% (B).Sensitivity Highlight: Project economics show the greatest leverage to overall metal prices, with NPV (5%) ranging from C$3.2 billion to C$10.2 billion (IRR: 14%-32%) at ±20% on all metals; even under additional +20% CAPEX and +20% OPEX sensitivities, applied on top of a 25% contingency already embedded in the base case, all scenarios deliver IRRs of 16% or better, and Scenario B provides additional scandium oxide upside with NPV(5%) of C$6.5 billion-C$8.1 billion (IRR: 18%-20%) at ±40% metal price.Scale and Longevity: The mine plan supports a multi-decade life of 25 years at a 120,000 tonnes-per-day processing rate, underpinned by a resource base of 609 Mt at 0.43% CuEq4 in the Measured and Indicated categories and 503 Mt at 0.41% CuEq4 in the Inferred category.High-Output Production Profile B: Envisioned as a conventional large-scale open-pit operation, the Project is expected to produce an average of over 74 kt of copper, 254 koz of gold, 376 koz of silver and 2.7 kt of cobalt annually during the first 10 years, with life-of-mine (LOM) average production of 67.6 kt Cu, 217 koz Au, 348 koz Ag, 2.5 kt Co, and 128 tonnes of scandium oxide per year. (NOTE: based on publicly reported 2024 North American cobalt mine production of approximately 3,800-4,000 tonnes (Natural Resources Canada; U.S. Geological Survey), the projected cobalt output is estimated to represent approximately 69% of current regional mined supply).Strategic Importance for Critical Minerals: The Project is positioned as a primary North American source of copper, scandium, and cobalt. With approximately 2.42 billion pounds of copper, 80 million pounds of cobalt and 2,415 tonnes of scandium oxide contained5 in the Measured and Indicated categories, the Project represents an important discovery of critical minerals.Stable, Supportive Jurisdiction: Located in a premier mining district in British Columbia, the Project benefits from a stable regulatory environment. The Company is committed to engaging with local First Nations in a respectful manner and to working toward positive and constructive relationships as the Project advances.Catalyst for Development: The PEA serves as the technical foundation for an immediate transition into a Pre-Feasibility Study (PFS), providing a clear roadmap for early works and permitting activities in 2026 and 2027.Farshad Shirvani, President and CEO of Doubleview Gold Corp., commented, "The results of this PEA confirm the scale, strength and long-term potential of the Hat Project. Delivering a post-tax NPV(5%) of up to C$6.73 billion and IRR of up to 23% at consensus prices, and even stronger metrics at spot prices, validates years of disciplined exploration and technical work by our team. Hat is demonstrating Tier 1 characteristics with a 25-year mine life, strong annual production profile and meaningful free cash flow generation. Importantly, the Project stands on its own without reliance on scandium, while still preserving significant upside from critical minerals as markets mature. We are excited to advance Hat to Pre-Feasibility and continue building a major Canadian critical metals project."Doubleview acknowledges that the Project is located on the traditional territories of the Tahltan Nation and the Taku River Tlingit First Nation, and recognizes their enduring relationship to and stewardship of the land and waters. Doubleview is committed to respectful, transparent, and ongoing engagement with First Nations and local communities whose territories overlap the Project area and access routes, with a focus on protecting water and the environment and advancing responsible development.PEA OVERVIEWThe PEA contemplates a conventional open-pit mine and processing operation with a 25-year mine life at a 120,000 t/d (42 Mt/a) plant throughput. Two processing pathways were evaluated, A1 and its alternative, A2, and B: the first alternative, A, is a Cu-Au-Ag-Co flotation concentrator with two recovery cases based on current metallurgical testwork, and A2, reflecting expected performance (Figure 1); and B, a full circuit that retains the base flowsheet and adds a downstream hydrometallurgical scandium recovery circuit (Figure 2).The tailings storage facility is a centreline-raised facility built with compacted cycloned sand from tailings underflow, and engineered drainage for stability, with site-contact waters (including seepage and pit dewatering) recycled to the process plant and final closure involving pond drainage and reclamation. The Project is expected to rely on grid power via an extended transmission line.Tables 1 to 3 summarize the key results of the PEA, including production, operating costs, capital expenditures, and the principal financial metrics; the sections that follow provide additional detail on the underlying assumptions, project design, and study outcomes.Table 1: PEA Study Summary-ProductionMetric UnitScenario A1Scenario A2Scenario BMining SummaryStrip ratiot:t1.60Production Summary LOMAverage Annual ThroughputMt42CuEq Head Grade6, 7%0.42Cu Head Grade%0.19Au Head Gradeg/t0.19Ag Head Gradeg/t0.51Co Head Gradeg/t77.73Sc Head Grade6g/t28.35Cu Recovery%8089858Au Recovery%6675898Ag Recovery%5353688Co Recovery%3030788Sc Recovery%N/A728Overall Mass of Tailings to Process9%N/A12.5Year of Production Start of Sc2O38yearN/A4Average Annual Cu Productionkt63.670.867.6Total Cu Productionkt1,590.51,769.41,689.9Average Annual Payable Cukt61.768.765.7Total Payable Cukt1,542.81,716.31,642.2Average Annual Au Productionkoz161.1183.1217.3Total Au Productionkoz4,028.24,577.55,432.0Average Annual Payable Aukoz153.1173.9207.5Total Payable Aukoz3,826.84,348.75,188.6Average Annual Ag Productionkoz271.3271.3348.0Total Ag Productionkoz6781.66,781.68,700.9Average Annual Payable Agkoz244.1244.1318.6Total Payable Agkoz6,103.46,103.47,965.3Average Annual Co Productionkt1.01.02.5Total Co Productionkt23.923.962.2Average Annual Payable Cokt0.80.82.3Total Payable Cokt19.119.156.3Average Annual Sc2O3 ProductiontN/A128.4Total Sc2O3 ProductiontN/A3,209.5Total Sc2O3 PayabletN/A3,049.0 Table 2: PEA Study Summary-Operating CostMetricUnitScenario A1Scenario A2Scenario BOperating Cost Average Mine Operating CostsC$/t-moved2.32Average Mine Operating CostsC$/t-milled6.03Processing Operating Cost10C$/t-milled7.937.9310.84Sc2O3 Processing Cost11C$/kg Sc2O3N/A939.55General & AdministrativeC$/t-milled2.562.562.56Total Operating CostsC$/t-milled16.2216.2221.92 Table 3: PEA Study Summary-Capital Expenditure and Financial MetricsMetricUnitScenario A1Scenario A2Scenario BCapital Expenditure Initial Capital CostsC$M3,5523,6013,828Sustaining Capital CostsC$M2,7552,7554,006Closure and Reclamation CostC$M503Financial Metrics Exchange RateCAD/USD1.37Long Term Copper PriceUS$/lb4.88Long Term Gold PriceUS$/oz3,272.60Long Term Silver PriceUS$/oz50.22Long Term Cobalt PriceUS$/lb19.57Long Term Scandium Oxide PriceUS$/kgN/A1,500Average Annual EBITDAC$M8861,0711,284Total EBITDAC$M22,16226,77032,101Average Annual Free Cash Flow (Pre-tax)C$M7569401,104Free Cash Flow (Pre-tax)12C$M18,90423,51127,592Total Provincial Tax (inc. BC Mineral Tax)C$M(4,029)(5,090)(6,019)Total Federal TaxC$M(1,274)(1,859)(2,308)Total TaxesC$M(5,303)(6,949)(8,327)Average Annual Free Cash Flow (Post-tax)C$M544662771Free Cash Flow (Post-tax)12C$M13,60116,56219,265Total Free Cash Flow (Pre-tax)13C$M15,35219,91023,764Total Free Cash Flow (Post-tax)12C$M10,05012,96115,437NPV 5% (Pre-tax)C$M7,88310,57611,567NPV 5% (Pre-tax)US$M5,7547,7208,443IRR (Pre-tax)%242923Payback (Pre-tax)yearsYear 5Year 4Year 6NPV 5% (Post-tax)C$M4,9636,7277,274NPV 5% (Post-tax)US$M3,6234,9115,309IRR (Post-tax)%192319Payback (Post-tax)YearsYear 6Year 5Year 7 Table 4 shows the Sensitivity analysis using after-tax NPV(5%) and after-tax IRR.Table 4: Sensitivity AnalysisVariableCase(%)Metal PriceScenario A1Scenario A2Scenario BNPV (5%) C$MIRR(%)NPV (5%)C$MIRR(%)NPV (5%)C$MIRR(%)Base Case Consensus forecast4,963196,727237,27419Copper Price-20US$3.90/lb Cu3,218154,807195,43316Copper Price+20US$5.86/lb Cu6,688238,632289,09922Gold Price-20US$2,618.08/oz3,625165,223195,53916Gold Price+20US$3,927.12/oz6,289228,222278,99622Metal Prices-20All metal prices1,708103,165142,99311Metal Prices+20All metal prices8,1182710,2333211,44426Initial CAPEX+20Variable per Scenario4,448166,222196,73216OPEX+20Variable per Scenario3,660165,438205,59116Scandium Oxide Price-40US$900/kg Sc2O3 6,49618Scandium Oxide Price+40US$2,100/kg Sc2O3 8,05020 MINERAL RESOURCE ESTIMATEDoubleview Gold Corp announced an update of the Mineral Resource estimate (MRE). This estimate followed the Micon International Ltd. (Micon) Mineral Resource estimate with an effective date of July 17, 2024. This MRE incorporates significant new data from the 2024 and 2025 exploration campaigns, with an effective date of February 4, 2026, and superseded the 2024 Micon estimate.Table 5: Hat MRE at a 0.2% CuEq Cut-Off Effective February 4, 2026Mineral Resource ClassificationTonnage(Mt)Average GradeMetal ContentCuEq(%)Cu(%)Au(g/t)Co(g/t)Ag(g/t)CuEq(Blb)Cu(Blb)Au(Moz)Co(Mlb)Ag(Moz)Measured2720.440.220.1876.260.372.611.111.4135.62.17Indicated3370.430.210.1976.810.393.211.311.8144.52.88Total M+I6090.430.210.1876.570.385.822.423.2280.15.05Inferred5030.410.180.1976.620.384.571.722.7766.24.19 Table 6: Hat MRE at a 0.2% CuEq Cut-Off as of February 4, 2026, Scandium Oxide ResourcesMineral Resource ClassificationTonnage(Mt)Sc Tonnage1(Mt)Average GradeSc (g/t)Metal ContentSc2O3 2 (t)Measured2723428.791,081Indicated3374228.761,334Total M+I6097628.772,415Inferred5036328.691,996 Notes: 1 Scandium tonnages represent 12.5% of the mineralized material by category, reflecting the proportion of tailings expected to be processed through a dedicated scandium leach circuit under current metallurgical design constraints.2 Scandium oxide metal content have been calculated using the metallurgical recovery of 72% and conversion factor from Sc to Sc2O3 of 1.534. Mineit's Qualified Person, Tomasz Wawruch, FAusIMM, completed the MRE, and has reviewed and approved the technical disclosure related to the MRE contained in this news release. Mr. Wawruch is a senior geology and mineral resource consultant independent of Doubleview. Mr. Gilles Arseneau, PhD., P.Geo., of ARSENEAU Consulting Services Inc., provided an independent review of this MRE.Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues.Inferred Mineral Resources are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves. The Mineral Resource Estimate was prepared in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum (CIM) Definition Standards for Mineral Resources and Mineral Reserves (2014), and CIM MRMR Best Practice Guidelines (2019).The effective date of the MRE is February 4, 2026.Metal contents have been calculated using the following metallurgical recovery factors: Cu = 85%, Au = 89%, Co = 78%, and Ag = 68%.Economic assumptions used include US4.80/lb Cu, US20.00/lb Co, US3,200/oz Au, US46/oz Ag, and a 2% NSR royalty.Mineral Resources are reported within optimized open pit constraints and 0.2% CuEq cut-off grade, based on a C7.93/t milled processing cost and C2.90/t milled general and administrative cost, with a mining cost of C3.01/t plus incremental mining cost increasing by C0.015/t for every bench below the reference level of 1,125 mRL.CuEq calculations do not include scandium. The formula used to calculate CuEq is: CuEq = [(((Ag × 46.0 × 0.68)/31.1035) + ((Au × 3200 × 0.89)/31.1035) + 0.0001 × (Co × 20.0 × 0.78 × 22.0462) + 0.0001 × (Cu × 4.8 × 22.0462 × 0.85))/(4.8 × 22.0462 × 0.85)], where all input variables are expressed in (ppm) and CuEq is expressed in percent (%).Rounding may result in minor variations between individual values and totals; such differences are not considered material to the MRE.Mineral Resource classification reflects the level of geological confidence and satisfies the uncertainty criteria appropriate for exploration and resource development. Additional drilling will be required to reduce uncertainty to the level expected for production planning. The MRE reflects the geological interpretation, drill-hole spacing, and estimation parameters available at the time of modelling. Any additional drilling is expected to influence the current outcome by improving confidence in the estimates and refining the geometry of the mineralized domains.The Mineral Resource results are presented in situ within the optimized pit. Mineralized material outside the pit has not been considered as a part of the current MRE tabulation. Calculations used metric units (metres, tonnes, g/t).A total of 97 diamond drill holes, comprising 49,548 m of core, were incorporated into the Mineral Resource Estimate. All drilling data used in the MRE were subject to standard QA/QC validation prior to inclusion.PROCESSING SCENARIOSThe PEA evaluates two processing scenarios: (A) a conventional Cu-Au-Ag-Co flotation concentrator at 120,000 t/d (42 Mt/a) with two recovery cases-A1 based on metallurgical testwork completed by Sepro Laboratories (Langley, BC) and A2 reflecting target/expected performance-and (B) a full circuit that retains the base flowsheet and adds a downstream hydrometallurgical scandium recovery circuit.The concentrator consists of crushing, grinding, flotation, concentrate handling, and tailings management, producing both a saleable approximately 25% Cu concentrate with co-product gold and by-product silver-cobalt credits and a pyrite concentrate enriched in cobalt; in the full-circuit case, the pyrite concentrate is roasted to generate sulphuric acid and a calcine that is then processed to recover cobalt, gold, silver, and copper; after stripping it will be precipitated as a sulphide to be admixed to the copper concentrate to improve grade, with the acid used to leach flotation tailings for scandium recovery, noting that the scandium circuit is a newer chemical process compared with the otherwise industry-standard flowsheet.Under A1 or A2 (Figure 1), the flowsheet produces a single saleable product-a copper concentrate with payable gold credits; the pyrite concentrate is not treated or marketed in this case and is only processed in B where the hydrometallurgical circuit enables recovery of cobalt (and additional Au-Ag) and supports the scandium circuit (Figure 2), which is planned to be constructed in a phased approach commencing in Year 3 of operations.Figure 1: Grinding and Flotation Flowsheet; Scenarios A1/A2 Report Copper Concentrate Only, while the Cobalt-Pyrite Flotation Stream Shown Is Included Only in Scenario BTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/289584_doubleview1.jpgFigure 2: Scenario B Hydrometallurgical Plant Block Flow Diagram, Showing Downstream Treatment of the Cobalt-Pyrite Stream and Flotation of Tailings to Recover Cobalt (and Au-Ag) and Scandium, Including Sulphuric Acid Generation to Support the Scandium CircuitTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/289584_94c53b19649fcaba_003full.jpgTable 7 summarizes the head grades, concentrate grades, and overall metallurgical recoveries from early testwork for the full circuit; A1 assumes only the reported recoveries to the Cu-Au concentrate, while the cobalt-pyrite concentrate and downstream recoveries are considered only in B.Early metallurgical testwork comprised metallurgical characterization studies under standard laboratory conditions to demonstrate metals recoverability for inclusion in the estimate of CuEq. No attempt was made to optimize flotation conditions, and more advanced flotation testwork was not undertaken. Consequently, the reported metallurgical recoveries are considered conservative, and it is reasonable to expect improvement with further testwork.A2, assumes improved copper and gold recoveries of 89% and 75%, respectively, reflecting expected performance from comparable Cu-Au porphyry flotation circuits following further optimization and testwork.Table 8 summarizes the recoveries assumption on each scenario.CAPITAL COST SUMMARYTable 9 presents the estimated capital cost breakdown for the three evaluated scenarios, separating initial CAPEX from sustaining CAPEX and reporting costs in C$M by major cost area (processing plant, mining, pre-stripping, infrastructure, tailings and water management, Indirects/EPCM, and contingency).Total initial CAPEX is estimated at C$3,552 million (A1), C$3,601 million (A2), and C$3,828 million (B), reflecting the higher processing plant scope and associated indirects/contingency in Scenario B.Total sustaining CAPEX is estimated at C$2,755 million (A1/A2) and C$4,006 million (B), with the increase in B driven primarily by the inclusion of the hydrometallurgical plant and scandium recovery circuit within sustaining capital, while mining, infrastructure, and tailings sustaining components remain broadly consistent across scenarios.OPERATING COST SUMMARYTable 10 summarizes the key operating cost and selling terms used in the PEA, reporting unit costs in C$/t moved, C$/t milled, and (where applicable) C$/kg of scandium oxide, together with concentrate transport and selling costs, TC/RC, and payability assumptions.Average site operating costs are estimated at C$16.22/t milled for Scenario A (concentrate-only) and C$21.92/t milled for B, with the increase in B driven by the addition of hydrometallurgical processing and acid generation (C$3.09/t milled) and scandium oxide processing costs (C$939.55/kg Sc₂O₃).On a payable metal basis, the study reports C1 cash costs of C$2.4/lb CuEq (A1), C$2.39/lb CuEq (A2), and C$2.89/lb CuEq (B) and AISC of C$2.79/lb CuEq (A1), C$2.78/lb CuEq (A2), and C$3.39/lb CuEq (B), reflecting the combined effects of recoveries, co-product/by-product credits, and the additional operating requirements of the full circuit.ECONOMIC RESULTSTable 11 summarizes the key economic assumptions and resulting financial metrics for Scenarios A1, A2, B, including the long-term price deck, cash flow generation, taxation, and discounted valuation at a 5% discount rate. Using an exchange rate of 1.37 CAD: 1.00 USD and long-term prices of US$4.88/lb Cu, US$3,272.60/oz Au, US$50.22/oz Ag, and US$19.57/lb Co (and US$1,500/kg Sc₂O₃ for B), the Project generates average annual EBITDA of C$886 million (A1), C$1,071 million (A2), and C$1,284 million (B). On a post-tax basis, NPV(5%) is estimated at C$4,963 million (A1), C$6,727 million (A2), and C$7,274 million (B) with corresponding post-tax IRRs of 19%, 23%, and 19%, and post-tax payback in Year 6 (A1), Year 5 (A2), and Year 7 (B). Total post-tax free cash flow is estimated at C$10,050 million (A1), C$12,961 million (A2), and C$15,437 million (B), reflecting the higher cash generation under the improved recovery case (A2) and the additional revenue streams in Scenario B, partially offset by the added capital and operating requirements of the hydrometallurgical and scandium circuits.SENSITIVITY ANALYSISSensitivity cases were evaluated for the key value drivers using after-tax NPV (5%) and after-tax IRR, including ±20% copper and gold prices, +20% initial capital, +20% operating costs and, for B, a ±40% scandium price sensitivity.Overall, the sensitivity analysis demonstrates that the Project's after-tax economics remain positive across the tested ranges, with the greatest variability in after-tax NPV(5%) and IRR driven by simultaneous changes in the overall metal price deck. Changes to copper and gold prices individually have a meaningful but smaller effect, while +20% initial CAPEX and +20% OPEX reduce value but do not eliminate Project attractiveness in any of the evaluated scenarios. Scenario B shows additional exposure to scandium oxide price, with after-tax NPV(5%) varying within a narrower range relative to the broader multi-metal price cases, indicating that scandium provides incremental upside while the base-case Cu-Au Project remains financially robust on its own.PERMITTING, RISKS, AND NEXT STEPSPermitting and EnvironmentalPermitting StatusThe permitting process will be supported by the continuation of environmental baseline studies, progression of engineering designs, and the initiation of socio-economic and cultural baseline studies.Due to the anticipated rate of resource extraction, it is expected that the Hat Project will be subject to both federal and provincial impact assessment pathways, so submission to both the Impact Assessment Agency of Canada (IAAC) and British Columbia Environmental Assessment Office (B.C. EAO) for their review is currently anticipated. Agency determination will decide the appropriate level of agency collaboration under the existing cooperation agreement for the Hat Project to acquire a provincial Environmental Assessment Certificate (EAC) and/or federal Decision Statement.The company will also submit a Joint Mines Act and Environmental Management Act Application through the B.C. Major Mines Office. Additional federal authorizations, including Fisheries Act approvals and compliance with Metal and Diamond Mines Effluent Regulations (MDMER), and applicable provincial permits will be obtained concurrently with other assessment and permitting steps. This will not only support protection of the immediate environment through the life of the Project but also respect the rights of First Nations and promote social and economic wellbeing for local communities.Tailings and Water ManagementThe Tailings Storage Facility (TSF) includes a perimeter dyke primarily constructed from compacted cycloned sand. This material will be sourced from the coarse underflow of tailings processed through an on-site cyclone plant. Using the centreline raise method, the dam is designed to be free-draining, lowering the phreatic surface to facilitate geotechnical stability. During operations, seepage from the TSF will be directed to the process plant as reclaim water. Upon closure, the supernatant pond will be drained, and the tailings and dam surfaces will be reclaimed with a granular trafficability layer, followed by a growth medium and native revegetation.The water management strategy prioritizes the reuse of site-impacted water, directing TSF water, contact water from the waste rock storage facilities, and open-pit dewatering to the process plant for use as make-up water.Key Risks and OpportunitiesProject-wideTailings Storage Facility:The location and geometry of the TSF are subject to refinement following geotechnical investigations of the potential site areas. Similarly, the anticipated availability of cycloned sand and the storage requirements for the facility may be adjusted once laboratory testing of the tailings is conducted.The integration of this future site-specific data presents a significant opportunity to optimize the TSF design.Mineral Processing:Limited metallurgical and comminution data introduce uncertainty in equipment sizing and operating cost inputs; however, early results indicate the ore should be amenable to conventional Cu-Au flotation, with potential upside from improved recoveries and reduced reagent consumption through optimization.The scandium circuit is less mature and is sensitive to acid economics and hydrometallurgical performance, but offers meaningful value upside if recoveries, product quality, and operating stability are confirmed at larger scale.Mine Design:Pit slope design criteria and mine scheduling are subject to elevated uncertainty due to the limited geotechnical database, including incomplete definition of structural controls, rock mass variability, and groundwater conditions. This creates downside risk to slope angles, strip ratio, and operating conditions if adverse structures or hydrogeology are encountered; however, it also provides a clear opportunity to materially improve design confidence and potentially optimize slope geometry, mine sequencing, and dewatering requirements through focused data acquisition and updated analyses.Capital Cost estimates:As a PEA-level estimate, capital costs remain subject to the inherent uncertainty of a preliminary design basis and limited engineering definition; however, significant effort was undertaken to develop the estimate using a defined scope, preliminary equipment sizing, and factored/benchmark-based costing with appropriate indirects and contingency. This work provides a credible foundation for decision-making at this stage while also highlighting clear opportunities to optimize capital intensity through further engineering definition, value engineering, and targeted trade-off studies (e.g., comminution configuration, tailings strategy, infrastructure/power, and construction execution approach).Scandium specific:Scandium provides strategic upside given its small, concentrated global supply base and the growing premium placed on secure, qualified supply, but it carries higher execution and commercial risk due to limited scale-up testwork (variability, impurity control, reagent intensity), added residue-management and permitting complexity, and uncertainty around product specifications, pricing, and customer qualification.Next StepsResource:The Company is advancing the Project toward Pre-Feasibility by upgrading confidence in the current Mineral Resource estimate and improving definition of mineralization within the proposed mine plan area. The program will prioritize infill drilling to support conversion of Inferred Resources to Indicated (and, where appropriate, Measured), together with step-out drilling to test extensions of known mineralization and provide improved geological continuity for next-stage mine design, scheduling, and economic evaluation.Waste facilities:Field investigations will be conducted at potential TSF and waste rock storage sites to characterize subsurface conditions and identify suitable borrow materials for construction. These efforts will be supported by site-specific geotechnical and geochemical characterization of the tailings and waste rock. These data sets will inform a TSF design update to a Pre-Feasibility Study (PFS) level of engineering, encompassing an optimized siting and technology trade-off study.Metallurgy:Complete a comprehensive metallurgical testwork program on representative samples including comminution testwork (Bond Work Index, abrasion index, and related grindability tests) and metallurgical variability + locked-cycle flotation testing to define an optimal process flowsheet, mass balance, and optimized reagent scheme, and to produce samples for concentrate dewatering and preliminary smelter marketing.Progress the scandium work through targeted hydrometallurgical optimization including pulp density, free acidity/acid consumption, SX staging and extractant concentration, followed by an integrated pilot trial on bulk samples to validate scandium recovery, product quality, and circuit operability.Mine Design:A phased geotechnical program is recommended that includes re-analysis of existing boreholes (re-logging and detailed structural mapping, including oriented-core interpretation where available), establishment of geotechnical domains, targeted drilling and field mapping to confirm discontinuity sets and persistence, and hydrogeological data collection to constrain pore pressures and inflows. These data will support updated kinematic assessments and slope design analyses, refinement of inter-ramp and overall slope angles, and improved inputs to mine planning, risk management measures, and capital/operating cost estimates.Capital Costs Estimation:As the Project advances to PFS, the estimate will be progressively refined by advancing engineering to a higher level of definition, updating quantities and vendor inputs for major equipment and packages, tightening indirects and construction productivity assumptions, and executing focused optimization and constructability reviews to reduce contingency and improve overall cost confidence.NI 43-101 DISCLOSURE, QUALIFIED PERSONS, AND CAUTIONARY STATEMENTSQualified PersonsThe scientific and technical information in this news release has been reviewed and approved by the following Qualified Persons, each with respect to the matters within their area of expertise, (as defined under NI 43-101):Tomasz Wawruch, FAusIMM, Senior Geology and Mineral Resource Consultant of Mineit Consulting Inc. (responsible for the Mineral Resource estimate).Andrew Carter, EUR ING, B.Sc., CEng., MIMMM (QMR), MSAIMM, SME, of Magister Metallurgy (responsible for metallurgical studies and recovery processes).Shervin Teymouri, P.Eng., Mining Engineer of Mineit Consulting Inc. (responsible for project management, mining engineering, capital and operating cost estimates, and financial analysis).Andre de Ruijter, P.Eng., of Mineit Consulting Inc, (process design, process capital and operating cost lead).Franky Li, P.Eng., of EMM Consulting Pty Ltd (responsible for tailings management and TSF design, tailings capital and operating cost).Jayesh Rami, P.Eng., Infrastructure Engineer of Sacre-Davey Engineering Inc. (responsible for project infrastructure).Qualified Person ReviewThe scientific and technical information contained in this news release has been reviewed and approved by Shervin Teymouri, P.Eng., a Qualified Person as defined under National Instrument 43-101. Mr. Teymouri is a mining engineer and is independent of the Company.Preliminary Economic Assessment Cautionary StatementThe Preliminary Economic Assessment (PEA) for the Hat Project is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability. The PEA provides a conceptual mine plan and is based on low-level technical and economic assessments that are insufficient to support an evaluation of the economic viability of the Project or to establish Mineral Reserves. There is no certainty that the results of the PEA will be realized. Further exploration and site-specific engineering studies are required before a higher level of confidence can be established for the Project's economics.The economic analysis in the PEA is based on several assumptions including, but not limited to, long-term metal prices, foreign exchange rates, metallurgical recoveries, and capital and operating cost estimates. These assumptions are subject to significant risks and uncertainties, and actual results may differ materially from those projected. Readers are cautioned not to place undue reliance on the PEA or the forward-looking information contained in this release.Forward-Looking InformationCertain of the statements made and information contained herein may constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Often, these forward-looking statements can be identified using words such as "anticipates," "believes," "continue," "estimates," "expects," "forecasts," "intends," "plans," "projected," or the negatives thereof or variations of such words and phrases. Forward-looking statements in this news release include, but are not limited to, statements with respect to: the results of the Preliminary Economic Assessment for the Hat Project; the estimation of mineral resources; anticipated annual production of copper, gold, cobalt, and scandium; the after-tax NPV and IRR of the Project; forecasted AISC and Total Cash Costs; estimated initial and sustaining capital costs; the timing of a Pre-Feasibility Study; the timeline for permitting milestones and construction decisions; planned early works and infrastructure upgrades; and the Company's ability to maintain strong community and First Nations partnerships.Forward-looking statements are based on a number of assumptions that management considers reasonable at the time they are made, including assumptions regarding: the future prices of copper, gold, cobalt, and scandium; foreign exchange rates; metallurgical recoveries; the cost of essential consumables; and the geopolitical and regulatory climate in British Columbia. However, such statements involve known and unknown risks and uncertainties which may cause actual results to differ materially. These risks include but are not limited to inaccurate estimation of mineral resources; volatility in metal prices; the results of future exploration and development activities; liquidity and financing risks; failure to obtain necessary permits; geotechnical conditions; and changes in applicable mining laws. The PEA is preliminary in nature and includes Inferred mineral resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as mineral reserves. Except as required by law, the Company undertakes no obligation to update or revise forward-looking information as conditions change.Non-GAAP Financial MeasuresThe Company has included certain performance measures in this news release that are not specified, defined, or determined under Generally Accepted Accounting Principles (GAAP). These non-GAAP measures are common in the mining industry but do not have standardized definitions and may not be comparable to similar measures presented by other issuers. Readers should not consider these measures in isolation or as a substitute for performance measures prepared in accordance with GAAP.Total Cash Costs: The Company calculates total cash costs as the sum of mining, processing, refining and transport, G&A, and royalty costs. Cash costs per unit are calculated by dividing the total cash costs by the payable Copper Equivalent (CuEq) units.All-In Sustaining Cost: AISC is a non-GAAP financial measure comprising of total cash costs, sustaining capital expenditures to support ongoing operations, and closure costs. AISC per unit is calculated by dividing the total all-in sustaining costs by the payable CuEq units.Sustaining Capital: This is a supplementary financial measure reflecting cash-basis expenditures expected to maintain operations and sustain production levels over the life of the mine.About Doubleview Gold Corp.Doubleview Gold Corp., a mineral resource exploration and development company based in Vancouver, British Columbia, Canada, is publicly traded on the TSX Venture Exchange (TSXV: DBG), the OTCQB (DBLVF), the Berlin Stock Exchange (GER: A1W038), and the Frankfurt Stock Exchange (1D4). Doubleview identifies, acquires, and finances precious and base metal exploration projects in North America, particularly in British Columbia. The Company increases shareholder value through the acquisition and exploration of quality gold, copper, cobalt, scandium, and silver properties-collectively critical minerals-and through the application of advanced, state-of-the-art exploration methods. Doubleview's portfolio of strategic properties provides diversification and mitigates investment risk.About Mineit Consulting Inc.Mineit Consulting Inc. (Mineit) is an independent mining engineering consulting company providing specialized expertise in project management, geological modelling, Mineral Resource estimation, mining engineering, metallurgical, and process engineering. Mineit led and prepared the Hat Project MRE and PEA, with assistance from other engineering firms, for the Hat Project in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum (CIM) Definition Standards on Mineral Resources and Reserves.For further information, please contact:Doubleview Gold CorpVancouver, BCFarshad ShirvaniPresident & CEOInstitutional Line: (604) 607-5470T: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information." In particular references to the Mineral Resource Estimate and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289584 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries ACN Newswire

OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries

ANTWERPEN, BELGIUM, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - This marks the 11th time the company has been recognized as a Leader. OMP believes this recognition underscores its consistent delivery of innovative solutions such as UnisonIQ and Unison Decision-Centric Planning. It reflects a market shift toward AI-driven supply chain planning, and the growing demand for platforms that unify strategy, execution, and intelligence in real time.Advancing intelligent planning for the most complex supply chain needsTrusted by Fortune 500 leaders such as AstraZeneca, BASF, Johnson & Johnson, and Procter & Gamble, OMP continues to advance supply chain planning through Unison Planning™, its proven end-to-end platform. Open, cloud-native, and AI-driven, the platform is built to meet the evolving demands of process and discrete global supply chains, including chemicals, consumer goods, life sciences, paper and packaging, tires and building products, and metals.Unison Planning™ incorporates UnisonIQ, OMP's AI orchestrator that unifies AI agents, assistants, and engines into one powerful framework. Designed for the agentic age of supply chain planning, UnisonIQ embeds continuous intelligence throughout the platform, giving organizations a foundation for proactive, autonomous decision-making grounded in deep industry expertise."Agentic AI is fundamentally reshaping how supply chains operate and compete," says Paul Vanvuchelen, Chief Executive Officer at OMP. "Organizations that embrace this shift will turn volatility into strategic advantage."Accelerating decision velocity for the entire supply chainOMP's Unison Decision‑Centric Planning elevates supply chain performance by uniting human expertise, advanced AI, real‑time intelligence, and rapid scenario evaluation to drive decision velocity and improve decision quality across the enterprise."With comprehensive supply chain intelligence and AI-powered anticipation, Unison Decision-Centric Planning enables organizations to gain earlier visibility into disruption, evaluate its impact, and prepare the next move with clarity and confidence," says Philip Vervloesem, Chief Commercial & Markets Officer at OMP.About the Gartner Magic QuadrantThe 2026 Gartner Magic Quadrant for Supply Chain Planning Solutions: Process Industries, released in March 2026, evaluates vendors based on their Ability to Execute and Completeness of Vision, helping global companies identify the right partners in a complex and fast-evolving market.We believe this recognition comes alongside OMP's strong performance in the 2026 Gartner Critical Capabilities for Supply Chain Planning Solutions Process Industries report, where it had been ranked in the highest two positions across all Use Cases. OMP also continues to receive strong customer ratings on Gartner Peer Insights™, reflecting positive feedback from enterprise users.For more information about OMP's position as a Leader in the Gartner Magic Quadrant and the future of supply chain planning, read the full report.Meet OMP at the Gartner Supply Chain Symposium/Xpo™OMP will participate in the 2026 Gartner Supply Chain Symposium/Xpo™, where customers will share practical insights on intelligent, decision-centric supply chains:Procter & Gamble will present key learnings from its collaboration with OMP at the Symposium/Xpo™ US, highlighting how integrated planning and end-to-end visibility drive measurable business impact.AstraZeneca will present its journey toward decision-centric autonomous planning at the Symposium/Xpo™ EMEA, highlighting how it is transforming processes and capabilities to achieve excellence.About OMPOMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, plastics & packaging, tires and building products - benefit from using OMP's unique Unison Planning™.Gartner, Magic Quadrant for Supply Chain Planning Solutions, Pia Orup Lund, Joe Graham, Buse Aras, Jan Snoeckx, Eva Dawkins, Julia von Massow, 18 March 2026.Gartner, Critical Capabilities for Supply Chain Planning Solutions: Process Industries, Julia von Massow, Eva Dawkins, Jan Snoeckx, Buse Aras, Joe Graham, Pia Orup Lund, 18 March 2026.Gartner and Magic Quadrant are trademarks of Gartner, Inc., and/or its affiliates.Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.Solution and product inquiriesContact OMPMedia inquiriesKira Perdue (Carabiner)SOURCE: OMP Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
在 2026 年 Gartner(R)《供應鏈規劃解決方案:流程工業》魔力象限(TM) 報告中,OMP 在「願景完整性」與「執行能力」兩大指標上均位居首位 ACN Newswire

在 2026 年 Gartner(R)《供應鏈規劃解決方案:流程工業》魔力象限(TM) 報告中,OMP 在「願景完整性」與「執行能力」兩大指標上均位居首位

比利時安特衛普, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 這是該公司第11次獲評為「領導者」。OMP 認為,此項殊榮彰顯了其持續提供創新解決方案(如 UnisonIQ 和 Unison 決策導向規劃)的實力。這反映了市場正朝向 AI 驅動的供應鏈規劃轉變,以及市場對能即時整合策略、執行與智慧的平台的日益增長的需求。為最複雜的供應鏈需求推動智慧規劃OMP 獲得阿斯特捷利康、巴斯夫、強生及寶潔等《財星》500 強企業的信賴,並持續透過其經實證的端到端平台 Unison Planning™,推動供應鏈規劃的進展。該平台具備開放、雲原生及 AI 驅動的特性,專為滿足流程型與離散型全球供應鏈的演變需求而打造,涵蓋化學品、消費品、生命科學、紙張與包裝、輪胎與建築材料,以及金屬等產業。Unison Planning™ 整合了 OMP 的 AI 協調器 UnisonIQ,將 AI 代理、助理與引擎統一於一個強大的框架之中。UnisonIQ 專為供應鏈規劃的「代理時代」而設計,將持續性智慧嵌入整個平台,為企業奠定基礎,使其能基於深厚的產業專業知識,進行主動且自主的決策。「代理式 AI 正在從根本上重塑供應鏈的運作與競爭模式,」OMP 執行長 Paul Vanvuchelen 表示。「擁抱這項轉變的企業,將能將市場波動轉化為戰略優勢。」加速整個供應鏈的決策速度OMP 的 Unison 決策導向規劃(Unison Decision‑Centric Planning)透過整合人類專業知識、先進 AI、即時智慧及快速情境評估,提升供應鏈績效,從而推動企業整體的決策速度並改善決策品質。「憑藉全面的供應鏈智慧與 AI 驅動的預判能力,Unison 決策導向規劃能讓企業更早預見干擾因素、評估其影響,並以清晰且充滿信心的態度籌劃下一步行動,」OMP 首席商務與市場官 Philip Vervloesem 表示。關於 Gartner 魔力象限2026年3月發布的《2026年Gartner供應鏈規劃解決方案魔力象限:流程工業》報告,依據供應商的「執行能力」與「願景完整性」進行評估,協助全球企業在複雜且快速演變的市場中識別合適的合作夥伴。我們相信,這項認可與 OMP 在《2026 年 Gartner 流程工業供應鏈規劃解決方案關鍵能力報告》中的優異表現密不可分——該報告中,OMP 在所有應用場景中均名列前兩名。此外,OMP 在 Gartner Peer Insights™ 上持續獲得客戶的高度評價,反映出企業用戶的正面反饋。欲進一步了解 OMP 在 Gartner 魔力象限中的領導者地位以及供應鏈規劃的未來發展,請閱讀完整報告。於 Gartner 供應鏈研討會/博覽會™ 親臨 OMP 攤位OMP 將參與 2026 年 Gartner 供應鏈研討會/博覽會™,屆時客戶將分享關於智慧型、以決策為中心的供應鏈之實務見解:寶潔公司將在美國場次(Symposium/Xpo™ US)分享與 OMP 合作的重要經驗,重點闡述整合式規劃與端到端可視性如何帶來可量化的商業效益。阿斯特捷利康將在歐洲、中東及非洲場次(Symposium/Xpo™ EMEA)展示其邁向以決策為中心的自主規劃之旅,重點說明該公司如何透過轉型流程與能力以達成卓越表現。關於 OMPOMP 透過提供市場上最卓越的數位化供應鏈規劃解決方案,協助面臨複雜規劃挑戰的企業脫穎而出、成長並蓬勃發展。來自消費品、生命科學、化學、金屬、紙業、塑膠與包裝、輪胎及建築材料等廣泛產業的數百家客戶,皆因採用 OMP 獨有的 Unison Planning™ 而受益。Gartner,《供應鏈規劃解決方案魔力象限》,Pia Orup Lund、Joe Graham、Buse Aras、Jan Snoeckx、Eva Dawkins、Julia von Massow,2026年3月18日。Gartner,《供應鏈規劃解決方案關鍵能力:流程工業》,Julia von Massow、Eva Dawkins、Jan Snoeckx、Buse Aras、Joe Graham、Pia Orup Lund,2026年3月18日。Gartner 及 Magic Quadrant 均為 Gartner, Inc. 及其關聯公司的商標。Gartner 並不認可其出版物中所提及的任何公司、供應商、產品或服務,亦不建議技術使用者僅選擇評級最高或其他獲特殊標示的供應商。Gartner 出版物反映的是 Gartner 商業與技術洞察組織的觀點,不應被視為事實陳述。Gartner 對本出版物不作任何明示或暗示的保證,包括任何適銷性或適用於特定目的的保證。Gartner Peer Insights 的內容包含個別終端使用者基於自身經驗所提出的意見,不應被視為事實陳述,亦不代表 Gartner 或其關聯公司的觀點。Gartner 不對本內容中所述的任何供應商、產品或服務予以背書,亦不就本內容的準確性或完整性作出任何明示或暗示的保證,包括任何適銷性或特定用途適用性的保證。解決方案與產品諮詢聯絡 OMP媒體諮詢Kira Perdue (Carabiner)消息來源:OMP Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Wellgistics Health Inc. 簽署價值 1.05 億美元的意向書,以評估收購 Neuritek Therapeutics, Inc. 的可能性;該公司致力於開發治療神經系統及精神疾病的創新療法 ACN Newswire

Wellgistics Health Inc. 簽署價值 1.05 億美元的意向書,以評估收購 Neuritek Therapeutics, Inc. 的可能性;該公司致力於開發治療神經系統及精神疾病的創新療法

坦帕, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - Wellgistics Health, Inc.(「Wellgistics」或「本公司」)(納斯達克代碼:WGRX)今日宣布,已簽署一份非獨家且不具約束力的意向書(「LOI」),以評估潛在收購專注於神經科學研究的機構Neuritek Therapeutics。若這項擬議的全股票交易得以完成,旨在透過擴展其核心技術驅動的藥品分銷及服務業務周邊能力,強化 Wellgistics 現有的營收型醫療保健平台。透過涵蓋處方藥配送、批發分銷及 AI 驅動的患者用藥解決方案的整合生態系統,Wellgistics 串聯了製造商、醫療服務提供者以及遍布全國的獨立藥房網絡。本公司認為,納入一家以研究為導向的組織,將能強化藥物開發與商業化之間的協同效應,使公司得以更早與製藥合作夥伴建立聯繫、提升產品管線的透明度,並創造額外的營收機會;同時透過更整合且具差異化的平台,提升長期股東價值。本交易仍須待盡職調查完成、最終協議的協商與簽署、各方董事會批准,以及其他慣常的交割條件達成後,方能生效。無法保證雙方將簽訂最終協議,亦無法保證擬議交易將按目前預期的條款完成,甚至可能無法完成。該意向書不具約束力,亦不強制任何一方完成擬議交易。任何潛在交易的範圍、結構及條款仍在評估中,並可能因持續進行的盡職調查及協商而發生重大變更。作為更廣泛成長策略的一部分,本公司亦正積極評估醫療保健及生命科學領域的其他戰略機會。這些機會可能包括收購、合作夥伴關係或其他戰略交易。無法保證任何此類舉措將最終促成交易完成。關於 Wellgistics Health, IncWellgistics Health 是一家快速擴張、以科技為驅動的醫療保健平台,定位於藥品分銷與患者獲藥管道的核心。本公司已建立一個涵蓋批發分銷、處方藥配送及人工智慧驅動的獲取解決方案的整合型高效能生態系統,直接串聯製藥廠商、醫療服務提供者及全國性的獨立藥局網絡。透過整合基礎設施、數據與智能自動化,Wellgistics 正執行一套資本效率高的營運模式,旨在於龐大且分散的醫療保健市場中搶佔顯著市佔率。本公司致力於拓展高毛利收入來源、深化與製造商的戰略合作關係,並在整個平台上推動營運槓桿效應。憑藉獨特的端到端服務方案與嚴謹的執行力,Wellgistics 已做好準備加速成長、提升獲利能見度,並為股東創造超乎預期的長期價值。關於 Neuritek Therapeutics Inc.Neuritek Therapeutics Inc. 開發了一種基於生物機制的次世代療法,旨在治療創傷後壓力症候群(PTSD)的根本成因。Neuritek 首款上市療法為口服活性脂肪酸酰胺水解酶 1 型(FAAH1)抑制劑,該酶負責代謝內源性大麻素(AEA),亦是首個針對 PTSD 機制的治療方案。 該公司由威廉·哈普沃斯(William Hapworth)醫學博士創立,他不僅是臨床研究的先驅,更是一位擁有逾 30 年臨床經驗的執業精神科醫師。欲了解更多資訊,請造訪 www.neuritek.com ,或透過 LinkedIn 加入討論:neuritek-therapeutics-inc前瞻性陳述本新聞稿包含符合《1995年私人證券訴訟改革法案》及其他適用聯邦證券法定義義的前瞻性陳述。這些前瞻性陳述包括但不限於:關於潛在收購 Neuritek Therapeutics, Inc.(「Neuritek」)之陳述,包括任何交易的預期架構、估值、時程及完成可能性;意向書之初步且非約束性性質;任何此類交易可能帶來的戰略、營運及財務效益; 本公司協商並簽訂最終協議之能力;本公司取得任何必要融資之能力;任何被收購業務之整合;以及本公司的整體成長策略與未來表現。前瞻性陳述可透過諸如「可能」、「可能」、「將會」、「應」、「預期」、「預估」、「相信」、「意圖」、「計劃」、「預測」、「估計」、「潛在」、 「機會」、「目標」、「預測」、「持續」、「將」及類似表述。此等前瞻性陳述係基於當前預期、假設及估計,並受重大風險與不確定性影響,其中許多因素超出本公司控制範圍。可能導致實際結果與預期存在重大差異的重要因素包括但不限於:各方未能簽訂最終協議的風險;意向書被終止或未能促成交易完成的風險;擬議估值及交易條款具初步性質所帶來的不確定性(此等內容可能發生重大變更);未能以可接受條款取得所需融資或完全無法取得融資的風險; 任何交易預期效益未能實現的風險;將以研究為導向的組織整合至本公司現有業務所伴隨的風險;藥品或治療產品的開發、測試、監管批准及商業化相關風險,包括可能出現不利的臨床結果或延誤;監管及合規風險;以及本公司不時向美國證券交易委員會提交的文件中所述的其他風險與不確定性。前瞻性陳述僅反映其作出當日的狀況,不應過度依賴此類陳述。除適用法律要求外,本公司無義務更新或修訂任何前瞻性陳述。Wellgistics 媒體與投資者聯絡資訊媒體: media@wellgisticshealth.com 投資者關係: IR@wellgisticshealth.com 消息來源:Wellgistics Health, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders ACN Newswire

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders

TAMPA, FLA., Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization.The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business. Through its integrated ecosystem spanning prescription fulfillment, wholesale distribution, and AI-driven patient access solutions, Wellgistics connects manufacturers, providers, and a nationwide network of independent pharmacies. The Company believes that adding a research-focused organization could strengthen alignment between drug development and commercialization, enabling earlier engagement with pharmaceutical partners, improving pipeline visibility, and supporting incremental revenue opportunities while enhancing long-term shareholder value through a more integrated and differentiated platform.The transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, approval by the boards of directors of the respective parties, and other customary closing conditions. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms currently contemplated, or at all. The LOI is non-binding and does not obligate either party to complete the proposed transaction. The scope, structure, and terms of any potential transaction remain under evaluation and may change materially as a result of ongoing diligence and negotiations.The Company is also actively evaluating additional strategic opportunities across the healthcare and life science sectors as part of its broader growth strategy. These opportunities may include acquisitions, partnerships, or other strategic transactions. There can be no assurance that any such initiatives will result in completed transactions.About Wellgistics Health, IncWellgistics Health is a rapidly scaling, technology-driven healthcare platform positioned at the center of pharmaceutical distribution and patient access. The Company has built an integrated, high-performance ecosystem spanning wholesale distribution, prescription fulfillment, and AI-powered access solutions, directly connecting pharmaceutical manufacturers, healthcare providers, and a nationwide network of independent pharmacies.By combining infrastructure, data, and intelligent automation, Wellgistics is executing on a capital-efficient model designed to capture significant share in large and fragmented healthcare markets. The Company is focused on expanding high-margin revenue streams, deepening strategic manufacturer relationships, and driving operating leverage across its platform. With a differentiated end-to-end offering and disciplined execution, Wellgistics is positioned to accelerate growth, enhance earnings visibility, and deliver outsized long-term value for shareholders.About Neuritek Therapeutics Inc.Neuritek Therapeutics Inc. has developed a next-generation bio-mechanism based treatment, treating the root cause of Post-Traumatic Stress Disorder (PTSD). Neuritek's first to market treatment is an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1), the enzyme responsible for metabolizing anandamide (AEA) and the first mechanisms-based treatment for PTSD. The company was founded by Doctor William Hapworth MD., a pioneer in clinical research and a practicing psychiatrist with over 30 years' experience.Learn more at www.neuritek.com or join the conversation at LinkedIn, neuritek-therapeutics-incForward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. These forward-looking statements include, without limitation, statements regarding: the potential acquisition of Neuritek Therapeutics, Inc. ("Neuritek"), including the anticipated structure, valuation, timing, and likelihood of completion of any transaction; the preliminary and non-binding nature of the letter of intent; the potential strategic, operational, and financial benefits of any such transaction; the Company's ability to negotiate and enter into definitive agreements; the Company's ability to obtain any required financing; the integration of any acquired business; and the Company's broader growth strategy and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will," and similar expressions.These forward-looking statements are based on current expectations, assumptions, and estimates and are subject to significant risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; uncertainties related to the preliminary nature of the proposed valuation and transaction terms, which may change materially; the risk that any required financing is not obtained on acceptable terms or at all; the risk that anticipated benefits of any transaction are not realized; risks associated with integrating a research-focused organization into the Company's existing business; risks related to the development, testing, regulatory approval, and commercialization of pharmaceutical or therapeutic products, including the possibility of unfavorable clinical results or delays; regulatory and compliance risks; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and undue reliance should not be placed on such statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Essex Bio-Technology Reports Robust Results for FY2025, Turnover Soars 8.6% to HK$1814 million, Net Profit up 3.5% to HK$ 318.1 million, Total Dividend Increases by 16.7% to HK14 Cents per Share ACN Newswire

Essex Bio-Technology Reports Robust Results for FY2025, Turnover Soars 8.6% to HK$1814 million, Net Profit up 3.5% to HK$ 318.1 million, Total Dividend Increases by 16.7% to HK14 Cents per Share

Key Results Highlights:- Revenue Growth: 8.6% increase to approximately HK$1,813.8 million- Net Profit Increase: 3.5% rise to HK$318.1 million, driven by operational efficiency- Final Dividend: Proposed final dividend of HK7.0 cents per share, bringing total dividend for 2025 to HK14.0 cents per share, a 16.7% surge from HK12.0 cents in 2024- Net Cash & Cash Equivalents: HK$782.7 million (HK$557.2 million as at 31st December 2024)Regulatory Milestones:- NMPA Approval: Multi-dose Diquafosol Sodium Eye Drops approved in July 2025; multi-dose Sodium Hyaluronate Eye Drops approved in January 2026 for registration and commercialisation in the PRC- BLA Acceptance: Bevacizumab ophthalmic injection BLA accepted by NMPA in August 2025, marking a crucial regulatory milestoneBusiness Developments:- Exclusive Distribution (Seefunge): Exclusive distribution of Seefunge's Emedastine Difumarate and Oxybuprocaine Hydrochloride Eye Drops in the PRC- Exclusive Distribution (Osteopore): Exclusive distribution of Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau.- Collaboration with Airdoc: Joint operation of Artificial Intelligence-based retinal businesses in the PRC- Strategic Collaboration with Kenvue: Promotion and marketing of Kenvue's consumer health products (Rhinocort(R), Motrin(R), Tylenol(R)) in the PRC.- International Innovation Accelerator: Signed MOU with Suzhou Industrial Park to launch cross-border life sciences accelerator.- First Overseas Market Entry: Beifushu(R) introduced to Singapore via Special Access Route at Singapore National Eye Centre.Intellectual Property and Market Presence:- Robust IP Portfolio: 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.- Extensive Distribution Network: Products available in over 14,600 hospitals and medical providers, and approximately 2,600 pharmaceutical stores across the PRCAwards and Recognition:- 2025 Top 500 Manufacturing Companies in Guangdong Province: Recognises industrial scale and comprehensive competitiveness- National Manufacturing Champion Enterprise: Affirms leading position in specialized biopharmaceutical segment- 2025 "Golden Kunpeng" China Financial Value Ranking – Most Valuable Listed Company for Investment: Highlights capital market recognition of growth potential- Participation at Asia-Pacific Academy of Ophthalmology Congress 2026: Showcasing key ophthalmology products and pipeline assets, strengthening engagement with regional eye care professionals and institutions.HONG KONG, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” and its subsidiary the “Group”, Stock Code: 1061.HK), a leading biologic Group that develops, manufactures and commercialises genetically engineered therapeutic recombinant bovine basic fibroblast growth factor (“rb-bFGF”), today announced robust annual results for the year ended 31st December 2025, with revenue up 8.6% to HK$ 1,813.8 million and net profit up 3.5% YoY to HK$318.1 million. The Group achieved multiple regulatory milestones and expanded its product portfolio through strategic collaborations, and Beifushu’s landmark entry into Singapore. These achievements underscore Essex's commitment to innovation and operational excellence, driving sustained revenue and profit growth.Diversified Growth Fueled by Flagship BiologicsThe Group achieved a consolidated turnover of approximately HK$1,813.8 million, with an increase of 8.6% as compared to approximately HK$1,669.8 million in 2024. Correspondingly, the Group’s profit increased by 3.5% to approximately HK$318.1 million as compared to approximately HK$307.2 million in 2024.The Beifushu(R) series and Beifuji(R) series, the Group’s flagship products drove growth, contributing 83.5% of turnover.The ophthalmology segment (“Ophthalmology”) recorded a turnover of HK$835.0 million, grew 8.2% year-on-year, led by Beifushu(R) unit-dose eye drops and supported by its preservative free design and expanding application scenarios, which cover multiple areas such as dry eye treatment and post-operative recovery, and contributions from Beifushu(R) eye gel, (Iodized Lecithin Capsules) and a range of unit-dose eye drops (Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops).The surgical segment (“Surgical”) turnover rose 1.8% year-on-year to HK$895.9 million, leveraging Beifuji’s broad clinical applications across multiple medical departments and strong market presence. It is also supported by numerous clinical guidelines and expert consensus, thereby laying a solid foundation for future indication expansion and sustained growth. In addition, Group Carisolv(R) dental caries removal gel, PELNACTM collagen-based artificial dermis and SCALGENTM double-layered artificial dermis had further strengthened and contributed to the Surgical business.Notably, Healthcare and Partner Services delivered a total turnover of approximately HK$82.9 million for the year ended 31st December 2025, representing a significant increase of 350% as compared to 2024. The growth was primarily driven by Dr. YaDian oral care products, online and offline healthcare services and CMO/CDMO services.Strengthening Financial Position and Shareholder ReturnsThe Group maintains a healthy financial position, with cash and cash equivalents of approximately HK$782.7 million as of 31st December 2025. Bank borrowings stand at HK$325.6 million, with a manageable repayment schedule over 5 years period. The Group’s gearing ratio is at 30.9% (2024: 28.8%), indicating disciplined financial management and ample liquidity.The Board is pleased to propose a final dividend of HK7.0 cents per ordinary share. Together with the interim dividend of HK7.0 cents per ordinary share, the total dividend for 2025 reaches HK14.0 cents, representing a notable year-on-year increase of 16.7% from HK12.0 cents in 2024, demonstrating the Group’s ongoing commitment to delivering greater returns to its shareholders.Broad Portfolio and Robust Pipeline Fuel Sustained GrowthThe Group’s business comprises three core segments: Ophthalmology, Surgical (wound care and healing) and Healthcare and Partner Services segment, with the Group’s six (6) flagship commercialised biologics, collectively referred to as the “bFGF Series”, which are marketed and sold in the PRC. Three of the bFGF Series were approved by NMPA as Category I drugs, and five are listed on the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance in the PRC.In addition, the Group offers a portfolio of commercialised preservative-free unit-dose eye drops, including Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops. The Group further expanded its ophthalmology franchise by obtaining NMPA approvals for the registration and commercialisation of multi-dose Diquafosol Sodium Eye Drops in July 2025 and multi-dose Sodium Hyaluronate Eye Drops in January 2026. The new launches target the PRC’s growing dry eye treatment market, complementing the Group’s Beifushu(R) ophthalmic repair series.As for the Surgical segment, the Group’s Carisolv(R) dental caries removal gel, Portable Ultraviolet Phototherapy Devices, PELNACTM collagen-based artificial dermis, SCALGENTM double-layered artificial dermis and Osteopore’s bioresorbable implants (Osteomesh(R) and Osteoplug(R)), are complementing the Group’s Beifuji(R) wound healing series.Strategic R&D Investment to Capture Emerging Market OpportunitiesThe Group is committed to pragmatically investing in new products and technologies to strengthen its product and R&D pipeline, with a mission to develop groundbreaking therapeutics that address unmet clinical and commercial needs. In 2025, total R&D expenditures were approximately HK$177.2 million, representing 9.8% of the turnover, of which approximately HK$139.3 million were capitalised.During the year, the Group’s Medical Scar Repair Gel obtained NMPA registration approval as a Class II medical device, expanding the Group’s footprint in the fast-growing high-end wound care and medical aesthetics markets, unlocking new growth drivers for long-term success.The global phase 3 clinical project of bevacizumab ophthalmic injection (EB12-20145P) has successfully completed patient enrolment across the PRC, Australia, European Union countries and the United States, with the last patient last visit was completed. A Biologics License Application (BLA) was accepted by NMPA in the PRC in August 2025.To amplify the Group’s presence in the Asia ophthalmic community and accelerate the market launch of new products, the Group participated in the 2026 Asia-Pacific Academy of Ophthalmology (APAO) Congress. The event provided a premium platform to showcase ophthalmic solutions, engage with regional clinical experts and partners, and build momentum for the rollout of its innovative ophthalmic products, reinforcing its global brand influence.The Group holds a total of 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.The Group currently has multiple R&D sites located in Zhuhai (PRC), Boston (United States), London (United Kingdom) and Singapore. These sites support the Group’s efforts to develop new therapeutics and recruit global talent.To date, the Group has 18 R&D programmes ranging from pre-clinical to clinical stages, with several ophthalmology programs currently in the clinical stage, specifically Bevacizumab intravitreal injection, SkQ1 eye drops and Cyclosporine eye dropsBroadening Commercial Reach Through Market Expansion and PartnershipsAs of 31st December 2025, the Group maintains an extensive network of 47 regional sales offices in the PRC and a strategic base in Singapore to facilitate market access into Southeast Asian countries. With a vast distribution network, the Group’s products are prescribed in more than 14,600 hospitals and medical providers, coupled with approximately 2,600 pharmaceutical stores, covering major cities throughout the PRC.During the year under review, the Group achieved multiple landmark breakthroughs in the PRC and overseas market expansion, unlocking new multi-dimensional growth momentum. In the overseas market, the Group’s flagship product Beifushu(R) was successfully introduced to Singapore via the Special Access Route at the Singapore National Eye Centre, marking the product’s first commercial launch beyond the PRC, and establishing a solid foothold to support the Group’s future expansion into Southeast Asia and global markets.In the PRC market, the Group entered into two landmark strategic partnerships during the year: a collaboration with global consumer health leader Kenvue, under which the Group will leverage its extensive nationwide commercial network in the PRC to carry out promotion, medical education and marketing for Kenvue’s selected consumer health products including Rhinocort(R) (Budesonide Nasal Spray), Motrin(R) (Ibuprofen Suspension/Drops), and Tylenol(R) (Paracetamol Drops/Suspension); and an exclusive distribution agreement for Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau, marking a strategic entry into the high-potential stomatology market. The partnerships broaden the Group’s healthcare business footprint, delivering strong synergies with its existing ophthalmology and regenerative medicine lines.To drive sustainable growth and expansion for its current and future products, the Group has been investing relentlessly in enhancing its competitiveness and broadening its reach by expanding the clinical indications for its commercialised products, increasing patient access in lower-tier cities across the PRC, developing complementary sales channels, and nurturing the healthtech e-platform to enhance patient access.The Group’s second factory at Zhuhai Hi-Tech Industrial Park, with a gross floor area of about 58,000 square meters for R&D, manufacturing, office and dormitory, is expected to complete in the period of 2026 -2027.Mr. Patrick Ngiam, Chairman of Essex, said “2025 was a standout year with Beifushu’s landmark entry into Singapore, driving robust growth through flagship products, innovation-focused R&D, and strategic partnerships. Essex remains committed to addressing unmet needs and driving long-term growth.We will proactively and systematically recalibrate operating and distribution costs to mitigate the negative impact on FY26 profit from the increase of VAT from 3% to 13% without disrupting our focus on Group development plans.”About EssexBio (1061.HK)EssexBio is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology. These products are marketed and sold through approximately 14,600 hospitals, supported by the Company’s 47 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, EssexBio maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
億勝生物科技2025全年業績穩健 收入升8.6%至18.14億港元 淨利潤升3.5%至3.18億港元 全年股息增加16.7%至每股14港仙 ACN Newswire

億勝生物科技2025全年業績穩健 收入升8.6%至18.14億港元 淨利潤升3.5%至3.18億港元 全年股息增加16.7%至每股14港仙

關鍵業績摘要:- 收入增長:收入同比增長8.6%至約18.14億港元- 淨利潤提升:得益於運營效率,淨利潤增長3.5%至3.18億港元- 末期股息:擬派末期股息每股0.07港元,2025年全年股息達每股0.14港元,較2024年全年股息的每股0.12港元大幅增加16.7%- 現金及現金等價物:7.83億港元(2024年12月31日:5.57億港元)研發里程碑:- NMPA批准:多劑量地誇磷索鈉滴眼液於2025年7月獲批;多劑量玻璃酸鈉滴眼液於2026年1月獲批在中國註冊和商業化。- BLA受理:貝伐珠單抗眼內注射液的生物製品許可申請(BLA)於2025年8月獲NMPA受理,標誌著重要的監管里程碑。商業發展:- 獨家代理(視方極):獲得浙江視方極富馬酸依美斯汀滴眼液、鹽酸奧布卡因滴眼液的獨家代理權。- 獨家代理(Osteopore):獲得Osteopore創新的牙科、正畸及頜面產品在中國內地、香港及澳門的獨家代理權。- 與鷹瞳科技合作:在中國實現眼底AI業務的聯合運營。- 與科赴戰略合作:在中國推廣及營銷科赴的消費者健康產品(雷諾考特(R)、美林(R)、泰諾林(R))。- 國際創新加速器:與蘇州工業園區簽訂戰略合作諒解備忘錄,推出國際創新加速器。- 首個海外市場准入:貝復舒(R)通過特別採用程序成功引入新加坡國家眼科中心。知識產權與市場佈局:- 強大的知識產權組合:持有合共121份專利證書或授權書,包括91項發明專利、15項實用新型專利及15項外觀專利。- 廣泛的銷售網絡:產品覆蓋中國內地超14,600家醫院和醫療機構以及約2,600家藥房。獎項與榮譽:- 2025年廣東省製造業企業500強:表彰產業規模及綜合競爭力- 國家級製造業單項冠軍企業:確認在專業生物製藥領域的領先地位- 2025「金鯤鵬」中國財經價值榜-最具投資價值上市公司:突顯資本市場對增長潛力的認可- 參與2026年亞太眼科學會大會:展示主要眼科產品及在研管線,加強與區域眼科專業人士及機構的聯繫。香港, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 億勝生物科技有限公司(「億勝生物」及其附屬公司「集團」;股份代號:1061.HK),一家領先的生物製藥企業,專注於研發、生產和銷售基因工程藥物重組牛鹼性成纖維細胞生長因子(「rb-bFGF」),今日公佈截至2025年12月31日止的強勁年度業績。集團收入同比增長8.6%至18.14億港元,利潤同比增長3.5%至3.18億港元。年內,億勝生物達成了多項監管里程碑,並通過戰略合作擴大了產品組合,同時成功將貝復舒(R)引入新加坡。這些成就彰顯了億勝對創新和卓越運營的承諾,持續推動收入和利潤的增長勢頭。旗艦生物藥推動多元化增長集團實現綜合營業額約18.14億港元,較2024年的約16.70億港元增長8.6%。相應地,集團溢利較2024年的約3.07億港元增長3.5%至約3.18億港元。集團的旗艦產品貝復舒(R)系列及貝復濟(R)系列持續帶動增長,佔總營業額的83.5%。眼科分部錄得營業額8.35億港元,同比大幅增長8.2%。其中,單劑量貝復舒(R)滴眼液憑藉無防腐劑設計及應用場景的持續拓展(覆蓋乾眼症治療及術後修復等多元領域)實現強勁銷售增長,貝復舒(R)眼用凝膠、適麗順(R)(卵磷脂絡合碘膠囊)和一系列不含防腐劑單劑量滴眼液(包括妥布黴素、左氧氟沙星、玻璃酸鈉、鹽酸莫西沙星及地誇磷索鈉滴眼液)亦作出持續貢獻。外科分部實現營業額8.96億港元,增長1.8%,主要受惠於貝復濟(R)系列產品在多個臨床科室的廣泛應用及其穩固的市場地位。同時,貝復濟(R)系列產品已獲多項臨床指南及專家共識支持,為未來適應症拓展及持續增長奠定基礎。此外,集團的Carisolv(R)齲齒凝膠、皮耐克可吸收性敷料、適可健雙層人工真皮修復材料等產品進一步增強並促進了外科業務的發展。值得注意的是,醫療保健及夥伴服務於截至2025年12月31日止年度錄得總營業額約8,290萬港元,較2024年大幅增長350%。增長主要來源於伢典醫生口腔護理產品、線上及線下醫療保健服務及CMO/CDMO服務等。穩健的財務基礎和股東回報集團維持穩健的財務狀況。截至2025年12月31日,集團錄得現金及現金等價物約7.83億港元。銀行借貸為3.26億港元,將在未來五年內按計劃償還。集團的資產負債比率為30.9%(2024年:28.8%),反映出集團具備嚴謹的財務管理能力和充足的流動性。董事會欣然建議派發末期股息每股普通股0.07港元。連同中期股息每股普通股0.07港元,2025年全年股息達到0.14港元,較2024年全年股息的0.12港元同比顯著增長16.7%,以彰顯集團致力於為股東創造價值的承諾。廣泛的產品組合及強大的研發管線支持持續增長集團業務由三個核心分部組成:眼科、外科(創傷護理及修復)以及醫療保健及夥伴服務分部。集團擁有六種於中國市場銷售的商業化生物製劑,統稱「bFGF系列」。其中三種bFGF系列為國家藥品監督管理局(「NMPA」)批准的國家一類新藥,五種被列入中國國家基本醫療保險、工傷保險和生育保險藥品目錄。此外,集團提供一系列商業化的不含防腐劑單劑量滴眼液,包括妥布黴素、左氧氟沙星、玻璃酸鈉、鹽酸莫西沙星及地誇磷索鈉滴眼液。集團進一步拓展其眼科產品組合,分別於2025年7月及2026年1月獲得NMPA批准多劑量地誇磷索鈉滴眼液及多劑量玻璃酸鈉滴眼液在中國註冊和商業化。新獲批產品聚焦於中國不斷增長的幹眼治療市場,以補充集團的貝復舒(R)眼表修復系列產品。外科方面,集團的Carisolv(R)齲齒凝膠及伢典醫生口腔護理產品,以及一系列產品及醫療器械(包括紫外線光療儀、皮耐克可吸收性敷料、Osteopore用於牙科手術的生物可吸收植入物(Osteomesh(R)及Osteoplug(R))及其他用於近視防控的醫療器械),共同補充了集團的貝復濟(R)創傷修復系列產品。戰略性研發投資以把握新興市場機遇集團致力於務實地投資新產品及技術,以強化其產品及研發管線,使命是開發解決未滿足的臨床及商業需求的突破性的療法。2025年,研發總支出約為1.77億港元,佔營業額的9.8%,其中約1.39億港元已資本化。年內,集團醫用疤痕修復凝膠獲批NMPA二類醫療器械註冊證,將集團業務拓展至快速增長的高端傷口護理及醫療美容市場,解鎖新增長動力以推動長期發展。貝伐珠單抗眼內注射液(EB12-20145P)的全球三期臨床項目已成功完成了在中國、澳大利亞、歐盟國家及美國的患者入組,最後一名患者已完成最後一次訪視。其生物製品許可申請(BLA)已於2025年8月獲中國NMPA受理。為提升集團在亞洲眼科領域的影響力,並加速新產品的市場推出,集團參與了2026年亞太眼科學會(APAO)大會。該會議提供了一個絕佳平台,用以展示眼科解決方案、與區域臨床專家和合作夥伴交流,並為集團創新眼科產品的推出積聚動能,從而提升全球品牌影響力。集團持有121份專利證書或授權書,包括91項發明專利、15項實用新型專利及15項外觀專利。集團目前於珠海(中國)、波士頓(美國)、倫敦(英國)及新加坡設立多個研發基地。這些基地為集團開發新療法和招募全球人才提供支援。截至目前,集團共有18項研發計劃處於臨床前至臨床階段,其中數項眼科項目處於臨床階段,具體包括貝伐珠單抗眼內注射液、SkQ1滴眼液及環孢素滴眼液。透過市場擴張與合作拓寬商業覆蓋截至2025年12月31日,集團於中國設有47間地區銷售辦事處,並於新加坡設有戰略基地,以促進其產品進入東南亞市場。憑藉龐大的分銷網絡,集團的治療產品在中國各地的逾14,600家醫院及醫療機構以及約2,600家藥房開具處方,覆蓋了中國各地的主要城市。回顧年內,集團在國內外市場擴張方面取得了多項里程碑式的突破,解鎖了多維度的新增長動力。在海外市場,集團的旗艦產品貝復舒(R)通過特別採用程序成功引入新加坡國家眼科中心,標誌著該產品首次進入中國以外地區,為集團未來進軍東南亞及全球市場奠定了堅實基礎。在國內,集團年內達成了兩項具里程碑意義的戰略合作:與全球消費者健康領導企業科赴合作,利用集團在中國廣泛的全國性商業網絡,對科赴精選的消費者健康產品(包括雷諾考特(R)、美林(R)及泰諾林(R))進行推廣、學術教育及營銷;以及與Osteopore簽訂獨家分銷協議,在中國內地、香港及澳門分銷其創新的牙科、正畸及頜面產品,標誌著集團戰略性進軍高潛力的口腔科市場。這些合作拓寬了集團醫療保健業務的版圖,並與其現有的眼科及再生醫學業務產生強大的協同效應。為推動現有及未來產品的可持續增長和擴張,集團一直不懈地進行投資,通過擴大其商業化產品的臨床適應症、增加中國較低線城市的患者可及性、開發補充銷售渠道,以及培育醫療科技電子平台以增強患者可及性,來提高其競爭力並拓寬覆蓋範圍。集團位於珠海高新區科技創新海岸的第二間工廠,建築面積約58,000平方米,用作研發、生產、辦公及宿舍,預計將於2026或2027年間完工。億勝生物主席嚴名熾先生表示:「2025年對億勝來說是具有里程碑意義的一年,貝復舒(R)成功引入新加坡,集團亦依託其核心產品、創新研發及戰略合作,實現穩健增長。未來,億勝將繼續致力於滿足未被滿足的臨床需求,推動集團長期發展。我们將主動、系統性地優化運營及銷售成本,以缓解增值税由3%上调至13%对2026财年利润带来的不利影响,同时保證集團發展規劃的穩步推進。」關於億勝生物(股票代碼﹕1061.hk)億勝生物是一間專注於研發、生產和銷售基因工程藥物b-bFGF的生物製藥企業,擁有包括貝復舒(R)、貝復濟(R)、貝復新(R)在內的六種基因工程藥物在中國上市銷售。此外,公司還擁有包含一系列不含防腐劑單劑量滴眼液和適麗順(R)卵磷脂絡合碘膠囊等的多元化產品組合,主要應用於眼科及皮膚科處方藥領域的創傷修復及疾病治療。這些產品在公司於中國的47個區域辦事處的支持下,在逾14,600家醫院進行營銷和銷售。依託自身在生長因子和抗體技術領域的研發平台,億勝生物在多個臨床階段擁有强大的項目管線,涵蓋廣泛的領域和適應症。網址: http://www.essexbio.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
GMG Launches European Sales Team; G(R) Lubricant Patent Accepted for Europe ACN Newswire

GMG Launches European Sales Team; G(R) Lubricant Patent Accepted for Europe

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the Company has officially launched its European sales activity. During the week of March 9th, GMG held a kick off training workshop in London where it brought together its new team members from various locations in Europe and UK for technical product and sales training.The GMG European Sales team numbers more than 10 professional sales executives based in Europe and UK who focus on lead generation, inside sales and executive sales business development for GMG's G® Lubricant and THERMAL-XR® products.Figure 1: Members of the GMG European Sales TeamTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/289529_gmg_figure1.jpgSeparately, the Company is also pleased to announce that it has been informed that the G® Lubricant patent in Europe has been accepted to be granted for a period of 20 years.Craig Nicol, CEO & Managing Director of the Company, commented "Building a sales force in key areas of the world is one of GMG's key activities it is focused on right now and to get the European team set up and running so fast has been a great achievement."Jack Perkowski, Chairman and Non-Executive Director of the Company, commented: "I congratulate the Company on building the European Sales team and look forward to hearing of future success."About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the size, term and success of GMG's European sales team and the eventual granting of and successful enforceability of the Company's G® Lubricant patent.Such forward-looking statements are based on a number of assumptions of management, including the European sales team will perform and the Company's G® Lubricant patent will be patented successfully. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that the GMG European Sales team does not successfully drive sales for the Company and the Company's G® Lubricant patent is not patented and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289529 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
雲頂新耀達成艾曲帕米鼻噴霧劑資產收購協議 強化心血管領域產品佈局 ACN Newswire

雲頂新耀達成艾曲帕米鼻噴霧劑資產收購協議 強化心血管領域產品佈局

香港, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀宣佈與箕星藥業香港有限公司(以下簡稱「箕星藥業」)達成資產收購協議 (The Asset Purchase Agreement),獲得艾曲帕米(Etripamil)鼻噴霧劑(擬定中文商品名:星必妥(R))在大中華區的開發、商業化及產品地產化權益。此次合作是公司深化心血管領域戰略佈局的重要舉措,進一步豐富了公司的產品管線、增強協同效應,持續鞏固公司在心血管疾病領域的發展。根據協議,雲頂新耀將向箕星藥業支付3000萬美元(相當於約人民幣206,937,000元)首付款,以及最高不超過2000萬美元(相當於約人民幣137,958,000元)的開發裏程碑付款。作為本協議的一部分,雲頂新耀將獲得箕星藥業於2021年5月簽訂的許可協議及相關附屬協議項下的權利、權益、主張、職責、義務及責任(不包括雙方約定的部分除外責任)。艾曲帕米鼻噴霧劑是一款新型、速效的鈣離子通道阻滯劑,采用便攜式鼻噴霧劑給藥,起效迅速且耐受性良好,可居家自行使用,可及性高。該藥物於2025年12月獲得美國食品藥品監督管理局(FDA)批准(美國商品名:CARDAMYSTTM),成為30多年來首款且唯一獲批用於成人陣發性室上性心動過速(PSVT)急性症狀性發作的療法,開拓了PSVT治療新場景。患者可在無醫療監督的環境(如居家)自行給藥,實現對病情的主動掌控,使疾病管理從依賴急診幹預轉向更加主動的院外管理。此外,艾曲帕米鼻噴霧劑正開發用於伴有快速心室率反應的房顫(AFib-RVR)適應症,II期臨床研究已取得積極結果,並計劃推進III期臨床研究,未來有望進一步拓展至更廣泛患者人群。在中國,艾曲帕米鼻噴霧劑用於治療PSVT的新藥上市申請已於2025年1月17日獲中國國家藥品監督管理局(NMPA)正式受理,並預計於2026年第三季度獲批,有望為PSVT患者提供全新的治療選擇。PSVT是一種以突發突止為主要特征的心動過速臨床綜合征,發作時心率極快且節律規則,通常持續數分鐘至數小時,患者症狀明顯且恐懼感強。PSVT急性發作的治療缺乏安全、便捷、可在院外自行使用的快速終止藥物,使患者在發作期長期處於「被動等待」狀態,缺乏真正意義上的「按需自救」工具。據悉,在中國,每1000中約有2.3-4人患有PSVT,估計總患者人數為300-600萬。AFib-RVR的特征是心率不規則,紊亂且快速,呈漸進式發作且不易自行終止,容易反複持續。目前中國的房顫患病率1.6%,對應患者人數約2000萬,並隨老齡化加劇呈上升趨勢。PSVT與AFib-RVR都會增加患者的失控感和心理負擔。整體來看,PSVT及AFib-RVR患者人群規模超過2500萬人,臨床需求遠未得到滿足,亟需更便捷、更高效的治療選擇。臨床數據方面,此次艾曲帕米鼻噴霧劑獲中國NMPA新藥上市申請受理是基於艾曲帕米關鍵性III期 RAPID 研究和中國III期 JX02002 臨床研究所取得的數據結果。JX02002研究達到了方案預設的主要終點,治療期出現的不良事件(TEAEs)在艾曲帕米治療組和安慰劑組之間相當。艾曲帕米鼻噴霧劑獲FDA批准是基於一項紮實的臨床試驗項目所得出的結論,該項目共收集了來自超1,800名參與者、超2,000次PSVT發作的安全性數據。這包括成功的3期RAPID試驗,這是一項在全球範圍內開展的、隨機、雙盲、安慰劑對照研究,結果於2023年發表在《柳葉刀》雜志上。RAPID試驗達到了其主要終點:自行使用艾曲帕米的參與者(N=99)中有64%在30分鐘內從室上性心動過速轉為竇性心律,而安慰劑組(N=85)為31%(HR = 2.62; p
More
同仁堂醫養(02667.HK)新股招股:尚在發展早期的中醫醫療龍頭股 估值幾何? ACN Newswire

同仁堂醫養(02667.HK)新股招股:尚在發展早期的中醫醫療龍頭股 估值幾何?

香港, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 在中醫藥文化傳承創新發展的時代浪潮中,一家承載著350餘年曆史積澱的醫療集團正昂首闊步走向國際資本市場。北京同仁堂醫養投資股份有限公司(以下簡稱"同仁堂醫養")於2026年3月20日正式啟動港股IPO招股,股票代碼為02667.HK,招股價範圍為7.30港元至8.30港元,中金公司擔任獨家保薦人,將於3月30日掛牌交易。憑借深厚的品牌底蘊、卓越的醫療服務能力和清晰的戰略布局,同仁堂醫養向全球投資者展示中國中醫醫療服務行業的無限潛力。本次全球發售H股總數為108,153,500股,其中香港公開發售10%,國際發售90%,基石投資占比46.15%,設置綠鞋。對港股投資者而言,這是一個值得注意的機會,中醫醫療服務賽道此前僅有固生堂,兩者模式在中醫細分賽道顯現出差異化,未來發展也各有側重,同仁堂醫養的加入將為投資者提供新的配置選擇。百年品牌背書,大流量的降維優勢作為中華老字號的傑出代表,"同仁堂"品牌始創於1669年,擁有超過350年的曆史傳承。這份厚重的文化積澱不僅代表著百年品質,更是國人心中標志化的民族品牌,也是其最寶貴的無形資產。招股書顯示,按2024年總門診人次及住院人次計,同仁堂醫養是中國非公立中醫院醫療服務行業中最大的中醫院集團,市場份額達1.7%。按2024年中醫醫療服務總收入計,公司以0.2%的市場份額在非公立中醫院醫療服務行業中排名第二。這一領先地位的確立,離不開"同仁堂"金字招牌的強大號召力。憑借深厚的客戶信任和業內公認的高質量中醫醫療服務及產品,公司以極具成本效益的方式吸引和留住大量客戶及醫療頂尖人才。2024年,公司銷售和分銷開支中的推廣費占總收入比例約為0.2%,遠低於行業平均水平,充分彰顯了品牌自帶的強大引流效應。這是百年品牌壁壘最直觀的量化體現,在獲客成本日益攀升的醫療服務行業,這一差距意味著巨大的利潤釋放空間。業績穩健增長,盈利能力持續攀升翻開同仁堂醫養的財務畫卷,一組組靚麗的數據勾勒出企業蓬勃發展的態勢:1.收入規模持續擴大: 2022年至2024年,公司總收入從9.11億元(人民幣,下同)增長至11.75億元,複合年增長率達13.6%。2025年前九個月,收入達8.58億元,持續穩健增長。其中,中醫醫療服務作為核心業務,貢獻了總收入的84%以上,展現出穩健的主業增長動力。2.盈利能力顯著增強: 2022年公司曾錄得淨虧損923萬元,但通過高效的整合運營和精細化管理,2023年迅速扭虧為盈,實現淨利潤4263萬元。2024年淨利潤進一步增至4620萬元,同比增長8.4%。若剔除上市開支等一次性因素,2024年經調整淨利潤達6173萬元,較2023年的4787萬元大幅增長29%,核心業務"造血"能力持續強化。3. 毛利穩步提升: 毛利從2022年的1.43億元增至2024年的2.22億元,複合年增長率高達24.8%,超過收入增速2倍,毛利率從2022年的15.7%提升至2024年的18.9%,盈利能力穩升,規模效應加速顯現。4. 現金流健康: 2024年現金轉化率達87.2%,有息債務占比僅11.56%,截至2025年9月持有現金2.25億元,資產負債表穩健。作為一家2019年版塊組建的企業,同仁堂醫養正處於"扭虧為盈→盈利加速"的關鍵拐點期。回顧固生堂的發展軌跡,2021年上市時也處於發展早期,此後三年收入和利潤CAGR分別高達19%和47%,股價從IPO至今已實現數倍漲幅。同仁堂醫養當前的發展階段與固生堂上市初期高度相似--盈利能力剛進入釋放通道,增長最快的階段可能尚未到來。分級診療網絡,三條增長曲線並行同仁堂醫養並未滿足於傳統醫療機構的單一模式,而是前瞻性地構建起覆蓋全國的分級中醫醫療服務網絡。截至最後實際可行日期,公司已擁有12家自有線下醫療機構及1家互聯網醫院,以及12家線下管理醫療機構,形成"連鎖醫院-基層醫療機構-互聯網醫院"三級聯動的完整生態。這一布局產生了顯著的協同效應。就診人次飆升:醫療網絡內總就診人次從2022年的132.1萬人次飆升至2024年的297.7萬人次,複合年增長率高達50.1%。2025年前九個月,就診人次已達253.6萬人次,同比增長21.5%。會員粘性強勁:會員累計人數從2022年底的43.6萬人增至2024年底的74.0萬人,複合年增長率達30.2%,截至2025年9月底進一步增至76.7萬人,顯示出強大的用戶粘性和品牌忠誠度。區域戰略清晰:公司以北京為戰略核心深入紮根,同時深耕長三角等經濟活躍地區。北京地區貢獻了近半數的收入,而浙江省作為公司拓展華東市場的橋頭堡,2024年中醫醫療服務收入達2.25億元,毛利率達22.6%,展現出強勁的區域增長潛力。根據信息,公司的擴張主要通過戰略收購、輕資產新建以及管理服務,是公司快速擴張的重要引擎。2022年,公司收購浙江"三溪堂"品牌下的醫療機構,成功切入長江三角洲地區市場。自收購以來,通過標准化管理和專業化運營整合,三溪堂保健院業績持續提升:2022年至2024年,收入由1.025億元增長到1.982億元,複合年增長率39.1%;門診人次由18.38萬增至38.23萬,複合年增長率約44.2%,充分驗證了公司強大的投後整合能力。2024年,公司進一步收購上海承志堂等機構,強化在長三角的業務布局。此外,其另一核心擴張戰略為向公立醫院提供管理服務,目前已在北京、貴州、新疆、陝西等省份合作十餘家醫療機構。未來募集資金也將加速這一模式的擴張布局,放大輕資產模式的利潤杠杆。根據招股書披露,公司即將在齊齊哈爾和北京順義開設自建院區,開始邁向中西醫結合和高端醫療布局。名醫資源匯聚,供應鏈精益管理中醫醫療服務,醫師是靈魂。同仁堂醫養深諳此道,持續打造高素質的中醫醫師團隊。截至最後實際可行日期:- 網絡內共有2,745名醫師加入並執業- 30名擁有國家級榮譽稱號的醫師,其中全國名中醫2名、全國老中醫藥專家學術經驗繼承工作指導老師13名、非物質文化遺產代表性傳承人5名- 擁有820名主任醫師或副主任醫師,占比近30%- 通過建立"名醫工作室"和師承教育體系,公司已孵化13個國家級或省級名醫學術傳承工作室,促進寶貴中醫學術理論和臨床經驗的代代傳承- 公司還設立同仁堂中醫學術咨詢專家委員會,涵蓋中醫腎病、婦科、內分泌、腫瘤等八大醫學專科,致力於中醫標准化和人才培養。"炮制雖繁必不敢省人工,品味雖貴必不敢減物力"--同仁堂的古訓在公司供應鏈管理中得到了完美詮釋。公司成立全資附屬公司北京通達,建立采購協同管理平臺,整合網絡內醫療機構的采購需求,實現規模經濟,增強議價能力。在質量管控方面,公司實施嚴格的供應商選擇標准和驗收流程,定期委托第三方機構進行隨機檢測。2023年的一次內部盲評中,北京同仁堂中醫醫院所使用的中藥飲片在北京多家知名中醫院中得分最高,充分證明了公司在質量管理方面的卓越表現。數智化賦能百年傳承,同仁堂擁抱AI浪潮公司於2020年成立同仁堂互聯網醫院,將傳統中醫診療與現代科技完美融合。客戶可享受線上預約、健康咨詢、複診診斷、電子處方等一站式服務,打破了時空限制,讓優質中醫醫療資源惠及更廣泛人群。截至最後實際可行日期,在互聯網醫院注冊的醫師累計提供超過84.9萬次在線咨詢,覆蓋全國各地。公司還與超過500家外部藥店建立合作關系,實現"線上診療+線下配送"的業務閉環,打造線上線下融合便捷服務體驗。同仁堂不僅是百年工藝的傳承者,更是數智化轉型的排頭兵,正通過與用友等戰略夥伴的深度合作,將AIoT、大數據等數字技術深植於業務的每一個細胞。傳統"經驗主義"正被"數據主義"取代,同仁堂構建了"全鏈智能"的質量溯源體系,為核心產品提供了數字化護城河。2026年1月,同仁堂與北京市經信局簽訂任務合同書,支持開展"人工智能中藥新藥開發平臺",構建十萬級方劑數據庫,通過AI技術為中藥新藥開發裝上"智慧大腦"。同仁堂醫養作為大健康終端,未來有望借助AI技術打破傳統服務時空限制,通過搭建智能化健康管理平臺,整合線上線下資源,為用戶提供個性化的健康監測、養生指導與遠程康養服務,實現從"治已病"向"治未病"的智慧化躍遷。戰略藍圖清晰,估值空間可期發展階段紅利:中醫醫療在港股中仍屬於稀缺標的,公司當前處於盈利加速的早期階段,隨著業務進入規模化擴張期,其利潤釋放空間值得期待。品牌溢價尚未充分定價:三百年品牌帶來的巨大流量,意味著每年節省的營銷開支相當於數千萬元級別的"隱形利潤"。隨著收入規模擴大,品牌壁壘的經濟價值將進一步放大。管理服務的輕資產模式:管理服務板塊從2022年至2024年收入增長700%,毛利率超70%,是高確定性的利潤增長極。這條輕資產第二曲線若持續放量,將顯著改善公司整體的盈利結構和ROE。集團協同的生態價值:公司是同仁堂集團"制藥-零售-醫養"大健康閉環的關鍵一環,與其他成熟版塊相比,發展空間巨大,上市後將享受集團資源的持續輸入。這種生態協同價值在當前估值中可能尚未被充分反映。隨著3月20日招股的正式啟動,同仁堂醫養正以紮實的業績、清晰的戰略和廣闊的前景,向全球投資者展示中國中醫醫療服務行業的無限魅力。正如其名,"醫"與"養"的完美融合,不僅呵護著萬千民眾的生命健康,更將開創中醫醫療服務的新紀元。轉載自格隆匯 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
From SGD to Global Spending: How Singaporeans Can Avoid FX Fees While Travelling Overseas ACN Newswire

From SGD to Global Spending: How Singaporeans Can Avoid FX Fees While Travelling Overseas

SINGAPORE, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Travelling overseas is exciting, but foreign exchange (FX) fees can quietly add up and increase your overall trip expenses. Many Singaporeans are now exploring smarter ways to manage overseas spending, and a multi-currency debit card can help reduce unnecessary FX charges while shopping, dining, and booking activities abroad. Whether you are heading to Japan, Australia, Europe, or the US, understanding how FX fees work can help you stretch your Singapore dollars further. Even a 3% fee on a SGD 5,000 trip translates to SGD 150, which could easily cover a nice meal or attraction tickets.When spending overseas, banks typically apply a currency conversion spread and may also charge overseas transaction fees ranging between 2.5% and 3.5%. On top of that, dynamic currency conversion at merchants can add another 4-8% markup. These layered charges might not be obvious at checkout, but they can significantly increase your travel budget.With a bit of planning and the right payment tools, Singaporeans can minimise these costs and enjoy more transparent spending abroad.Understanding Where FX Fees Come FromBefore looking at solutions, it helps to understand how FX fees are structured. Most traditional credit and debit cards issued in Singapore apply a foreign transaction fee when you pay in a currency other than SGD. This fee usually combines the card network's conversion rate and an additional bank administrative charge.For example, if you spend the equivalent of SGD 1,000 in Bangkok or Seoul, a 3% fee adds around SGD 30 to your statement. Over a 10-day trip with shopping and dining expenses of SGD 4,000, total FX charges could reach SGD 120 or more. These amounts may seem small per transaction but can accumulate quickly across hotels, theme parks, transport passes, and shopping malls.How a Multi-Currency Debit Card Can HelpA multi-currency debit card allows users to hold and spend multiple foreign currencies directly from one account. Instead of converting SGD at the point of sale for every purchase, you can preload currencies such as USD, EUR, JPY, or AUD in advance. This setup can help reduce conversion fees and give you more control over exchange rates.For instance, if you are travelling to Japan and expect to spend the equivalent of SGD 3,000, you can convert SGD to JPY when rates are favourable before departure. If the exchange rate improves even by 1%, that difference could mean savings of around SGD 30 on your total spend.Many multi-currency debit cards also offer competitive interbank or near-interbank rates with low or zero foreign transaction fees. While terms vary by provider, this structure may result in lower overall costs compared to traditional cards. Additionally, you can track balances in different currencies via mobile apps, which helps you manage budgets more clearly during travel.Practical Ways Singaporeans Can Reduce FX ChargesBeyond choosing the right card, several practical habits can help minimise FX fees while shopping overseas.Pay in the local currency whenever possibleWhen a payment terminal offers the option to pay in SGD or the local currency, selecting the local currency can help you avoid dynamic currency conversion markups. Merchants may apply rates that are 4-8% higher than market rates when you choose SGD. On a SGD 2,000 shopping bill in Seoul, that difference could translate to an extra SGD 80 or more. Paying in the local currency often results in a more transparent rate from your bank or card provider.Plan large purchases in advanceIf you are considering buying luxury goods in Europe or electronics in Japan, estimating your total spend beforehand can help you prepare accordingly. Planning major purchases can also help you avoid last-minute conversions at less competitive airport rates.Avoid exchanging large sums at airportsAirport money changers often offer less competitive exchange rates compared to city money changers in Singapore or digital FX platforms. The difference might range from 1% to 3%. On SGD 2,000 exchanged at the airport, this gap could mean paying SGD 20 to SGD 60 more than necessary. Using a multi-currency debit card for most transactions can reduce the need to carry large amounts of cash.Monitor overseas ATM withdrawal feesWithdrawing cash overseas may involve both local ATM fees and your bank's overseas withdrawal charges. These combined costs can range between SGD 5 and SGD 15 per withdrawal, excluding FX spreads. Planning fewer, slightly larger withdrawals, or relying more on card payments, can help reduce repeated charges. Some multi-currency debit cards may offer more competitive ATM withdrawal terms, depending on the provider.Comparing Travel Spending OptionsCredit cards may offer travel rewards but often carry foreign transaction fees of around 3%. Using cash helps you to do away with card fees but requires you to exchange money upfront, sometimes at less competitive rates.A multi-currency debit card sits somewhere in between, combining digital convenience with potentially lower FX costs, while offering more flexibility. For frequent travellers visiting destinations like Malaysia, Thailand, Japan, Australia, or the US several times a year, this flexibility can make budgeting more predictable.Avoiding FX fees does not require complex strategies. Small adjustments in how you pay, when you convert currency, and which card you use can collectively reduce costs. While exchange rates fluctuate and fees vary across providers, informed decisions can help you minimise hidden charges and make the best of your overseas trips.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
中國新城鎮2025年內溢利大增35.5% 持續派息回饋股東 ACN Newswire

中國新城鎮2025年內溢利大增35.5% 持續派息回饋股東

香港, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 2026年3月20日,專注於中國內地投資及優質資產持有運營的中國新城鎮發展有限公司(「中國新城鎮」或「公司」,及其附屬公司,統稱「集團」;香港股票代號:01278.HK)欣然宣佈截至2025年12月31日止12個月(「2025年」或「回顧期」)之經營業績。回顧期內,集團持續深化改革轉型路徑,在攻堅克難中交出高質量答卷。2025年集團錄得主營業收入約3.89億元(單位:人民幣,下同),同比增長15%;年內溢利7571萬元,同比增長35.5%;母公司權益擁有人應占溢利總額約7329萬元,同比增長65.4%。董事會建議派發末期股息為每股普通股0.0025港元。主營業務穩健增長,固收業務持續優化回顧期內,集團繼續保持穩健經營。2025年公司實現城鎮化投資收入2.31億元,同比增長約25%,主要因為城鎮化項目投資餘額較去年同期增加,對應項目投資收入增加。實現物業租賃及管理費收入人民幣約1.00億元,包括物業租賃收入人民幣0.76億元、物業管理費收入人民幣0.24億元。實現工程建設收入人民幣5,717.5萬元。面對國內外複雜經濟形勢,集團依託股東無錫交通集團與國開金融的資源優勢,充分發揮「地方國資+央企金融機構」的業務網路效應,做好主營業務的管理及運營,實現了穩定增長。2025年集團城鎮化投資業務穩中有進,持續貢獻穩定現金流。截至2025年12月31日,固定收益投資組合總額達人民幣33.66億元。優質資產運營穩中提質。武漢光穀物業項目面對市場壓力實現「止跌回升」,通過精准招商與服務升級,年底平均出租率回升至75%,保證了投資性房地產估值的穩定。借力股東資源聚焦戰略轉型,拓展增長新空間2025年集團緊抓國家大力發展新質生產力的政策機遇,結合股東的資源優勢,圍繞積體電路、新能源、新材料、高端裝備製造、環保等新經濟方向進行優質股權項目儲備,戰略並購路徑逐步聚焦及清晰,擬通過持有不同行業的優質資產,打造穩健收入及現金流以及後續新業務領域的增長空間。值得一提的是,集團發揮股東協同優勢,在實現經營業績穩健增長的同時,融資工作取得重大突破,成功發行15億元離岸人民幣債券,用於現有債務的再融資,進一步降低了債務成本並優化了期限結構,為集團後續業務的發展提供可持續的資金支援。持續派息,提供穩定股東回報2025年集團擬派發末期股息0.0025港幣/股,加上中期已經派發的中期股息0.0016港幣/股,2025年集團全年派息金額約3900萬港元。自2023年中期恢復派息以來,集團累計已經派發及擬派發股息金額達到了約1.2億元人民幣,顯示了持續回報股東的意願和行動。未來展望展望2026年,作為「十五五」開局之年,集團將緊扣國家新質生產力導向,聚焦戰略新興產業與信創產業,加速業務轉型。固收業務穩中提質,保障現金流;優化武漢光穀等核心資產運營,提升效能。同時,積極儲備優質股權項目,力爭戰略並購實質突破,持續為股東創造核心價值。關於中國新城鎮發展有限公司中國新城鎮(香港聯交所股份代號︰1278)為中國內地的投資及優質資產運營商。自2014年起,本集團順應中國新城鎮化發展趨勢優化了業務模式,以「投資+下游產品運營」的業務模式,通過固定收益類項目投資作為出發點,持有優質資產管理及運營,同時以市場為導向,全力在新材料、半導體、高端裝備製造等新經濟領域拓展股權投資業務,積累行業投資經驗。本新聞稿由千里國際顧問有限公司代表中國新城鎮發展有限公司發佈。如有垂詢,請聯絡:中國新城鎮發展有限公司 ir@china-newtown.com千里國際顧問有限公司Fancy Wang fancywang@maxima.hk Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More